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ABSTRACT 
Millions of people worldwide have been infected with human immunodeficiency 
(HIV). Highly active antiretroviral therapy (HAART) has substantially improved the clinical 
management of HIV-1 infection. Inclusion of HIV protease inhibitors (PIs) in HAART has 
substantially improved clinical outcomes of HIV infected patients. However complete 
eradication of virus poses an unmet goal. Major challenge with current anti-HIV drug 
regimen is the inability of PIs to attain sufficient concentrations in sanctuary sites such as 
brain resulting in persistent viral replication and may lead to viral resistance. Sub-therapeutic 
concentration of PIs in brain leads to drug resistance and HIV associated dementia. One of 
the major factors which limit central nervous system (CNS) permeation of PIs is the presence 
of efflux proteins on brain capillary endothelial cells. There are several reports demonstrating 
that PIs are substrates of efflux proteins which limit their oral bioavailability and brain 
permeation. Various approaches have been employed to evade the efflux and improve the 
bioavailability, however improving brain absorption still remains as an elusive goal. The 
overall objective of this dissertation project was to improve oral and brain bioavailability of 
Amprenavir (APV) by prodrug strategies targeting nutrient transporters to bypass P-
glycoprotein (P-gp) mediated efflux. APV has low bioavailability and negligible brain 
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absorption which is attributed by low aqueous solubility, efflux mediated by multidrug 
resistance proteins, extensive metabolism and protein binding. In order to improve oral 
bioavailability and absorption across blood brain interfaces, di-peptide and amino acid 
prodrugs of APV (Val-Val-APV, Gly-Val-APV, Val-APV) were synthesized and evaluated 
for interaction with efflux and influx transporters, enzymatic hydrolysis, and bioavailability. 
These prodrugs targeting peptide transporters were demonstrated to evade P-gp mediated 
efflux and exhibit better permeability characteristics compared to APV. All these prodrugs 
have higher aqueous solubility. Enzymatic stability and metabolism studies demonstrated 
that these prodrugs undergo enzymatic hydrolysis and regenerate parent drug which exerts 
pharmacological action. Oral and brain absorption of prodrugs was much higher as compared 
to APV in Sprague-Dawley rats. Thus transporter targeted prodrug modification of P-gp 
substrates could lead to shielding of these drug molecules from efflux pumps and improve 
bioavailability of PIs and other P-gp substrates.  
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CHAPTER 1 
INTRODUCTION 
Overview 
Millions of people worldwide have been infected with human immunodeficiency 
virus (HIV) and the syndrome remains among the top five fatal diseases. Two different 
retroviruses, HIV-1 and HIV-2, cause HIV infection in humans. Both are enveloped positive-
stranded RNA viruses belonging to lentivirus sub-family. HIV-1 is responsible for the 
majority of infections globally. AIDS dementia complex (ADC) or HIV-associated dementia 
(HAD) develops in about 20 per cent of HIV infected patients who progress to AIDS. 
Although the development of highly active antiretroviral therapy (HAART) has greatly 
slowed the progression from HIV infection to AIDS and improved the clinical treatment of 
AIDS related diseases, the eradication of HIV/AIDS remains a major medical challenge. 
HAART constitutes a combination of protease inhibitors (PIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs). 
Despite of their very good antiviral efficacy, PIs suffer from low and variable oral 
bioavailability, negligible brain permeation and poor pharmacokinetic (PK) profiles. Low 
and variable oral bioavailability is attributed by poor aqueous solubility, high affinity for 
membrane efflux proteins, high protein binding and extensive metabolism by CYP enzymes. 
Also, the existence of sanctuary sites such as brain parenchyma for HIV-1 may potentially 
endanger the efficacy of long-term therapy. Sub-therapeutic concentrations of PIs in the 
sanctuary sites like brain, lung and bone marrow cause persistent viral infection and may lead 
to viral resistance. Blood brain barrier (BBB) presents a significant challenge to the delivery 
of therapeutic agents to the brain. Tight junctions prevent free diffusion of small polar 
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molecules across this barrier. However, entry of large lipid soluble molecules is also limited 
across BBB by the presence of several ATP binding cassette (ABC) efflux transporters i.e., 
P-glycoprotein (P-gp) and multi-drug resistance associated proteins (MRPs) which efficiently 
prevent entry of drug molecules into the central nervous system (CNS).  
Various strategies have been employed by researchers to evade the efflux and 
improve bioavailability. These approaches include co-administration of efflux protein 
inhibitor or modulator to control the expression and functional activity of efflux proteins, 
utilizing various formulations such as nanoparticulate systems, and chemical modification of 
drugs such that efflux can be evaded. Co-administration of modulators and inhibitors may 
affect the physiological activity of efflux proteins which efflux xenobiotics and toxins from 
cells. This may lead to adverse events and toxicities. Chemical modifications such as prodrug 
approach has the advantage that activity of efflux proteins is not affected. This pro-drug 
approach does not require any additional augmenting agent which may lead to toxicity. One 
of these non-substrate strategies is targeted prodrug approach. In this approach not only 
evading the efflux proteins, but also influx transporters such as nutrient transporters can be 
utilized. This approach involves utilization of influx proteins which facilitate transport of 
polar nutrients such as amino acids and peptides.  
Prodrugs can be designed by conjugating amino acid/di-peptide promoiety such that 
they can be recognized and translocated by amino acid and peptide nutrient transporters 
expressed on epithelial (intestinal ) and endothelial (brain capillary endothelial cells) cells. 
Another advantage of these prodrugs is the promoieties released after regeneration of parent 
drug are not toxic. When a compound binds to a nutrient transporter, it triggers a 
configurational change in the transport protein allowing its translocation across the 
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membrane and it is subsequently released into the cytoplasm. During this process the 
substrate is not freely available to efflux transporters located on the inner leaflet of the cell 
membrane. Circumventing P-gp/MRP2 mediated efflux not only increases absorption across 
intestinal mucosa but also decreases repetitive exposure to metabolizing enzymes in 
intestinal lumen. In addition to the possibility of enhanced intestinal permeation, prodrug 
derivatization of compounds may offer additional pharmaceutical, pharmacokinetic and 
toxicokinetic advantages such as better chemical stability, solubility and toxicity profiles. 
Therefore, transporter targeted prodrug derivatization strategy offers several possibilities that 
may prove to be advantageous for systemic delivery of PIs.  
In this dissertation project novel amino acid and di-peptide prodrugs of amprenavir 
(APV) have been designed and synthesized such that the modified compounds become 
substrates of nutrient transporters. These prodrugs were evaluated for their interaction with 
efflux proteins, influx transporters, enzymatic stability, metabolism and systemic 
bioavailability  
Statement of the Problem 
Protease inhibitors are considered to be the most important therapeutic agents to date 
for the treatment of AIDS. Currently available PIs approved by FDA include Saquinavir, 
Ritonavir, Nelfinavir, Lopinavir, Amprenavir, Fosamprenavir, Indinavir, Atazanavir, 
Tipranavir and Darunavir. Despite of good antiviral efficacy, PIs suffer from unfavorable 
physicochemical and pharmacokinetic properties. APV has low aqueous solubility, low oral 
absorption and fast biotransformation into inactive metabolites. When used both alone and in 
combination with other antiretroviral agents, amprenavir has been demonstrated to be a 
highly effective inhibitor of HIV replication that reduces HIV-1RNA levels and is associated 
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with improved CD4+ cell counts (St Clair et al., 1996; Sadler et al., 1999; Veronese et al., 
2000). Currently available formulations of amprenavir are as 50 mg and 150 mg soft-gelatin 
capsules or as a 15 mg/mL oral solution, with a recommended oral dose of amprenavir 
(capsules) for adults and adolescents of 1200 mg bid, without specific food or fluid 
requirements. Despite its absorption profile being relatively good for a protease inhibitor, 
dosing regimens of up to eight capsules twice daily are required to achieve effective plasma 
concentrations. This can be a problem for some patients, especially since they are likely to be 
facing a significant pill burden if they are following a highly active antiretroviral therapy 
(HAART) regimen (Falcoz et al., 2002). Oral bioavailability of APV is limited to 14-26%. 
Such low bioavailability is primarily attributed to extensive cellular efflux mediated by efflux 
protein P-glycoprotein (P-gp) and first-pass metabolism mediated by enzyme cytochrome 
P450 3A4 (CYP3A4). Predominantly localized P-gp limits the absorption of orally 
administrated drugs. Abundantly expressed in the liver and gut wall, CYP3A4 is responsible 
for the extensive first-pass metabolism of. APV is a good substrate for both P-gp and 
CYP3A4 (Kempf et al., 1997; Adkins and Faulds, 1998; Edwards et al., 2002). The efflux of 
drug molecules by P-gp back to intestinal lumen or blood capillaries further increases the 
drug exposure to cellular as well as luminal enzymes and thus causing extensive drug 
metabolism. The monotherapy of APV is restricted because of its low bioavailability. The 
combination of APV with ritonavir/ketoconazole may boost the plasma concentration of 
APV. However, high doses of drugs are required in order to reach sufficient therapeutic level 
of drug concentration, which may cause drug resistance and cytotoxicity. In order to 
circumvent the cellular efflux mediated by P-gp and extensive first-pass metabolism 
mediated by CYP3A4 and thus improving the oral absorption and bioavailability of APV, 
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novel amino acid and di-peptide conjugated prodrugs of APV were designed and 
synthesized. These amino acid, di-peptide prodrugs may become the substrates of the influx 
transporters expressed on intestinal epithelium and brain endothelial cells and bypass the P-
gp mediated efflux.   
Objectives 
The objectives of this dissertation project are:  
a. To synthesize relevant peptide and amino acid prodrugs of APV and characterize 
these compounds in terms of  their molecular weights, aqueous solubilities and buffer 
hydrolysis 
b. To study the interaction of the synthesized prodrugs of APV with the respective 
influx transporters, affinity of the prodrugs towards efflux proteins and metabolizing 
enzymes in vitro using appropriate cell culture models 
c. To study protein binding, enzymatic hydrolysis  and bioreversion of prodrugs in vitro  
d. To investigate oral bioavailability of APV and prodrugs in vivo in Sprauge-Dawley 
rats 
e. To study permeability characteristics of APV an prodrugs using in vitro blood brain 
barrier model (rat brain endothelial cells co-cultured with astrocytes) 
f. To conduct in vivo brain microdialysis studies with amino acid prodrugs to study their 
brain absorption properties 
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CHAPTER 2 
LITERATURE REVIEW 
This chapter provides overview of HIV (human immunodeficiency virus) infection, 
current clinical management, and role of protease inhibitors in HIV therapy, setbacks of 
current therapy. This chapter also discusses about role of efflux proteins and influx 
transporters in oral and brain absorption. Various strategies to circumvent P-gp, MRP 
mediated efflux, and prodrug approach. This chapter would facilitate understanding of the 
research goals and findings presented in subsequent chapters. 
Introduction to HIV and AIDS 
Acquired Immune Deficiency Syndrome (AIDS) is caused by HIV. HIV is different 
from most other viruses since it compromises the host immune system. Over one million 
Americans are living with HIV/AIDS today. Worldwide, the figure is over 30 million AIDS 
is the final stage of HIV infection. It can take years for a person infected with HIV, even 
without treatment, to reach this stage. Having AIDS means that the virus has weakened the 
immune system to the point, at which the body is vulnerable for other opportunistic 
infections. 
HIV Virus 
Two different retroviruses, HIV-1 and HIV-2, cause HIV infections in humans. HIV 
enveloped single stranded RNA viruses belonging to lentivirus sub-family. HIV-1 is major 
cause of infections worldwide. The cross sectional view of HIV virion is shown in Figure 1. 
7 
 
 
HIV is an enveloped complex retrovirus.  The genetic information is encoded by ~9-
kb RNA and each virion has two copies of RNA. HIV-1 genome consists of nine separate 
genes encoding for a total of 3 structural polyproteins (Env, Gag and Pol), 4 accessory 
proteins (Vif, Vpr, Nef and Vpu) and 2 regulatory proteins (Rev and Tat ) (Frankel and 
Young, 1998). The outermost covering of the virus particle, referred as envelope, is a lipid 
bilayer derived from the host cell plasma membrane. HIV-1 is composed of two copies of 
single-stranded RNA enclosed by a capsid comprising the viral protein p24. The capsid 
environment also contains other viral proteins such as integrase and reverse transcriptase. 
This capsid is in turn encapsidated by a layer of another matrix protein (MA) called p17. The 
HIV-1 RNA is part of a protein nucleic acid complex, which is composed of the 
nucleoprotein p7 and the reverse transcriptase p66 (RT). The viral particle contains all the 
Figure 1. Stucture of HIV virion. Adapted from US NIH 
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enzymatic equipment that is necessary for replication: a reverse transcriptase (RT), an 
integrase p32, and a protease p11. An envelope, which covers the viral core or nucleocapsid, 
is derived from host cell membrane. This core is mainly lipoidal in nature and contains some 
viral proteins. The major HIV protein associated with this envelope is gp120/41. The gp41 
glycoprotein traverses the envelope, gp120 is present on the outer surface and is non-
covalently attached to gp41. This functions as the viral antireceptor or attachment proteins. 
Both gp120 and gp41 glycoproteins have important role in the binding of HIV to cells in the 
infection process. Besides these surface proteins, HIV is also studded with human proteins 
(including class I and class II MHC molecules) acquired by the virus as it buds from the 
human cell membrane. 
Life Cycle of HIV 
HIV can only replicate inside human cells, therefore HIV life cycle can be divided 
into seven steps: entry to the cell, reverse transcription and integration, transcription and 
translation, and assembly and maturation (Figure 2). Life cycle of HIV-1 virus begins with 
binding of the virus with the CD4+ receptors present on the host cells (Dalgleish et al., 1984; 
Klatzmann et al., 1984). CD4+ receptors are present on the surface of many lymphocytes, 
which are critical part of body’s immune system. In addition to binding to CD4+ receptor, 
HIV virus also binds to either a CCR5 or CXCR4 co-receptor protein to get entry into the 
host cell. The virus then fuses with the host cell and releases its genetic material and RNA 
into host cells. An enzyme called reverse transcriptase then converts the single stranded HIV 
RNA to double stranded HIV DNA. Reverse transcriptase inhibitors are an important class of 
drug that inhibits the conversion of viral RNA to DNA.  
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Figure 2. Stages of HIV life cycle. Adapted from NIAID 
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Reverse transcriptase inhibitors were the first HIV medications, and are still a critical 
part of treating patients with HIV. Reverse transcriptase inhibitors can be divided into two 
classes, nucleoside and non-nucleoside analogues, based on the structure and the mechanism 
by which they inhibit viral reverse transcriptase. Once the genetic material of HIV virus is 
converted to DNA it enters the host cell nucleus and an enzyme called integrase facilitates 
the integration of viral DNA into the host cell DNA. This integrated HIV DNA is now 
known as provirus. This provirus may remain in latent state for many years producing few or 
no new copies of HIV. This ability to persist in certain latently infected cells is the major 
barrier for the eradication or cure of HIV. Activation of the host cell results in the 
transcription of viral DNA into messenger RNA (mRNA) with the help of an enzyme called 
RNA polymerase. This new viral mRNA forms the genetic material of the next generation of 
the virus. The viral RNA and viral proteins assemble at the cell membrane into a new virus. 
Amongst the viral proteins is HIV protease, which is require to process HIV proteins into 
their functional form. HIV-1 PIs, one of the most potent drugs for HIV-1 treatment acts by 
blocking this critical maturation step of the virus. Following assembly at the cell surface, the 
virus then buds forth from the cell, and is released to infect another cell. Unless treated, the 
virus spreads throughout the body and results in the destruction of the body’s immune 
system. The destruction of immune system leads to many opportunistic infections and further 
to many life-threatening complications. One important goal is to design new drug moieties 
which can interfere with HIV life cycle in its early stages or to develop drug moieties, which 
can prevent the entry of virus particles into the host cell. 
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HIV Associated Dementia 
AIDS dementia complex (ADC) or HIV-associated dementia (HAD) develops in 
about 20 per cent of HIV infected patients who progress to AIDS. The actual underlying 
mechanisms for the pathogenesis of ADC in adults and progressive encephalopathy in infants 
and children still remain unclear. In approximately 30 per cent of immunosuppressed HIV 
infected patients, the entry of virus into the central nervous system (CNS) initiates a 
syndrome which is characterized by progressive motor degeneration and behavioral 
abnormalities (Price et al., 1988). Although the virus infects the brain at an early stage of 
HIV infection, neurological complications including dementia, sensory neuropathy and 
myelopathy tend to occur at an advanced stage of AIDS. Cells primarily harboring the virus 
in brain are the microglial cells and macrophages. Macrophage activation within the CNS 
and peripheral nervous system (PNS) appears to be a critical factor in the development of 
HAD and sensory neuropathies (Kamerman et al.).  Brain cells, other than macrophages also 
get infected with HIV-1. Non-productive infection of astrocytes with the expression of nef 
and rev has been reported with HIV-related encephalopathy in infants (Tornatore et al., 1994; 
Ranki et al., 1995). Observed neuronal dysfunction and loss of neurons in advanced HAD 
(20-40% in the frontal lobe) may be due to indirect factors such as neurotoxins and 
cytokines. Astrocytosis induced during brain infection may also be a critical event in HAD, 
as dopamine system may be damaged, which may have profound effects in clinical 
manifestation of HAD.  
Current HIV Treatment Options 
The knowledge about the life cycle of HIV-1 and the necessity to combat the virus 
has led to the development of many anti-HIV agents. Currently, 25 drugs belonging to six 
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different categories had been approved by the US FDA for the treatment of HIV (Flexner, 
2007; Greene et al., 2008). As depicted in Figure 2, the life cycle of HIV-1 includes several 
steps starting from viral entry and finishing with maturation of released viral particles. 
Accordingly, drugs were designed to inhibit viral entry (by inhibiting the chemokine CCR5 
coreceptor), to inhibit viral fusion (by inhibiting TM/gp41), to inhibit reverse transcription of 
viral RNA into DNA (by inhibiting RT), to inhibit integration of viral DNA into host genome 
(by inhibiting IN) and/or to inhibit maturation of released viral particles (by inhibiting PR) 
Table.1 summarizes the current anti-HIV drugs belonging to different classes approved by 
the USFDA. 
Protease Inhibitors (PIs) 
Protease (PR) plays a prominent role in the maturation of released virions. It is a 99-
residue protein belonging to the class of aspartic acid proteases, functioning as a catalytic 
dimer (Pearl and Taylor, 1987; Oroszlan and Luftig, 1990; Wlodawer and Erickson, 1993; 
Louis et al., 2007). PR helps in processing Gag-Pol and Pol polyproteins into mature 
functional and structural proteins. In the absence of PR, the nascent virions are non-
infectious and hence the spreading of HIV-1 is halted. Thus, PR seems to be an indispensable 
target in the treatment of HIV-1. The presence of efflux transporters and extensive plasma 
protein binding (90–99%) of PIs lowers the effective concentration of drugs in the viral 
sanctuary sites (Nath and Sacktor, 2006; Kwara et al., 2008; Pokorna et al., 2009). In order to 
maximize drug concentration, a low dose of RTV (pharmacokinetic enhancer / booster) is 
administered. This combination significantly decreased HIV progression due to enhancement 
of pharmacokinetic properties of coadministered drug.  
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 Table 1. Summary of drugs approved by the USFDA for HIV treatment.   
Drug Category Generic name Brand Name® 
CCR5 Antagonists 
(entry inhibitors) 
Maraviroc Selzentry 
Fusion Inhibitors 
 
Enfuvirtide Fuzeon 
Non-nucleoside Reverse 
Transcriptase Inhibitors (NNRTIs) 
 
Nevirapine Viramune 
Delavirdine Rescriptor 
Efavirenz Sustiva 
Etravirine Intelence 
Rilpivirine 
 
Edurant 
Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) 
 
Zidovudine Retrovir 
Didanosine 
 
Videx 
 
Stavudine Zerit 
Lamivudine Epivir 
Abacavir Ziagen 
Tenofovir Viread 
Lamivudine Epivir 
Integrase Inhibitors 
 
Raltegravir Isentress 
Protease Inhibitors 
Saquinavir (SQV) Invirase 
Ritonavir (RTV) Norvir 
Indinavir (IDV) Crixivan 
Nelfinavir 
(NFV) 
Viracept 
Amprenavir 
(APV) 
Agenerase 
Fosamprenavir 
(FPV) 
Lexiva 
Lopinavir 
(LPV) 
Kaletra (in combination 
with RTV) 
Atazanavir 
(ATV) 
Reyataz 
Tipranavir 
(TPV) 
Aptivus 
Darunavir (DPV) Prezista 
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This significant finding was first reported by Kempf et al, where they have shown that RTV 
potently inhibited the cytochrome P450 (CYP)-mediated metabolism of SQV, IDV, NFV and 
APV (Kempf et al., 1997). This reported by Kempf et al, where they have shown that RTV 
potently inhibited the cytochrome P450 (CYP)-mediated metabolism of SQV, IDV, NFV and 
APV (Kempf et al., 1997). This finding was considered as a milestone in the development of 
HIV therapeutics and currently all the marketed PIs, expect for NFV, are co-administered 
with RTV. Currently marketed PIs are listed in Table 1.  
The introduction of highly active anti-retroviral therapy (HAART), i.e., combinations 
of PIs with nucleoside reverse transcriptase inhibitors (NRTIs) or non-nucleoside reverse 
transcriptase inhibitor (NNRTIs) has resulted in suppression of HIV viral replication and 
progression. However, this regimen encountered with many problems including: compliance, 
resistance, interactions and adverse effects. Compliance in HAART is frequently observed 
due to higher pill burden. The development of antiviral drug resistance due to high mutation 
rate and lack of proof reading capacity of viral RT also leads to treatment failure (Doyon et 
al., 1996; Mammano et al., 1998). Also, complications arise due to metabolism of PIs and 
NNRTIs via the same pathway (CYP-P450) (de Maat et al., 2003). The long term adverse 
effects of antiretrovirals such as visceral fat accumulation (within the abdomen, on the upper 
back and around the neck), metabolic disorders (hyperlipidemia, hypertriglyceridemia and 
insulin resistance), hepatotoxicity and increased cardiovascular risks still remains a major 
problem (Nolan et al., 2005; Shibuyama et al., 2006; Wohl et al., 2006). Taken together, 
although the current therapeutics are successful in reducing viral load, there are several 
disadvantages associated with them. Novel PIs with better pharmacokinetic properties, 
simple dosage regimen, little/no resistance and side effects are desirable at this point.  
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HAART has proven successful in suppressing systemic viral burden, but brain has 
proven to be a sanctuary site where the virus can reside relatively unchecked by therapeutic 
intervention (Thomas, 2004).  The major obstacle in the delivery of PIs to the brain is the 
blood brain barrier. In addition to the tight cellular junctions at BBB the presence of efflux 
transporters (P-gp, MRP) are the primary factors limiting the entry of PIs into the brain. All 
protease inhibitors are substrates of ATP dependent efflux pumps (P-gp, MRP) which 
actively extrude PIs from the brain.  Hence, brain serves as a sanctuary site for HIV-1 and 
potentially endanger the efficacy of long term therapy (Crowe and Sonza, 2000; Yeni et al., 
2004). Also, complete eradication of HIV-1 may not be possible due to latently infected cells 
in the CNS which can lead to drug resistance and finally treatment failure. Thus, the presence 
of efflux proteins and metabolizing enzymes may result low oral bioavailability and sub-
optimal drug concentrations, particularly in sanctuary sites, resulting in consumption of a 
large dose of PIs to maintain adequate drug concentration in the brain tissue leading to 
significant toxicity. Thus, in HIV pharmacotherapy, adequate drug concentrations in the 
brain are needed for anti-viral efficacy. For optimal brain delivery of the HIV protease 
inhibitors, circumvention of the membrane specific efflux transporters is essential. 
Brain Drug Delivery 
Several therapeutic agents are unsuccessful in treating CNS disorders due to 
ineffective delivery to brain. Drug delivery to brain poses a great challenge even though 
brain is highly perfused with blood flow. This is due to the physiological barriers which 
separate brain tissue from blood circulation and control transport of several compounds 
including nutrients. Barriers attributing to low brain bioavailability of drugs are BBB and 
BCSFB. Important functions of these barriers are to impede free diffusion between brain 
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fluids and blood, and to provide transport processes for essential nutrients, ions and 
metabolic waste products (Redzic, 2011). 
Treatment of neurodegenerative diseases, brain cancers and infections require 
therapeutic drug concentrations in the brain. Drug delivery to central nervous system (CNS) 
poses several challenges for researchers in drug development because of limited access for 
therapeutic agents. Low brain absorption of therapeutic agents is mainly attributed to two 
physiological barriers, blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier 
(BCSFB). BBB is formed by polarized endothelial cells of brain microvasculature and 
several other cell populations such as astrocytes and pericytes which support endothelial cells 
collectively in restricting entry and exit of nutrients and xenobiotics. The BCSFB is located 
at choroid plexus and formed by epithelial cells which are connected by tight junctions. 
Stroma and fenestrated blood vessels are present underneath the epithelial cells. These blood 
vessels lack tight junctions but tight junctions between epithelial cells restrict the entry of 
drugs into cerebrospinal fluid (CSF) (Scherrmann, 2002). Even though brain is highly 
vascularized, these barriers separate brain from general blood supply. BBB and BCSFB play 
an important role in controlling entry of nutrient and therapeutic agents into brain, thus 
maintain brain homeostasis. Other than cellular tight junctions, various efflux proteins such 
as P-glycoprotein (P-gp), multidrug resistance proteins (MRPs) and breast cancer resistant 
protein (BCRP) are highly expressed on BBB and contribute significantly to limit brain 
absorption of drugs.  
Blood-Brain Barrier (BBB) 
Brain is protected from foreign organisms and toxic substances by BBB. It is made up 
of three layers, inner endothelial cell layer which forms wall of brain capillaries, basement 
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membrane and feet processes of astrocytes and pericytes. Figure 3 is the schematic 
representation of BBB and other components of vascular unit and their arrangement. Brain 
capillaries have a complex morphology which provides special characteristics to endothelial 
cell layer with respect to diffusion of solutes. Brain endothelial cells (BECs) are 
interconnected by tight junctions (TJs) and occlude paracellular spaces. Moreover BECs 
exhibit minimal pinocytotic activity.  In addition these BECs are secluded by astrocytic end 
feet and pericytes on brain side which further restrict permeability of various drugs. Overall 
BBB exhibits very high transendothelial electrical resistance (TEER) values, around 1500 
Ωcm2, which is very high compared to other tissues which ranges from 3-33 Ωcm2  (Crone 
and Christensen, 1981). Thus BBB provides very high resistance to permeability of solutes, 
drugs and xenobiotics. As mentioned earlier other than BECs, other cell populations which 
attribute to barrier properties of BBB include astrocytes and pericytes. Both astrocytes and 
pericytes help in differentiation and maintenance of BBB function. Astrocytes account for 
60% of total non-neuronal cell population which provide biochemical support for endothelial 
cells, transport essential nutrients to nervous tissue and maintain extracellular ion balance. 
They also play a crucial role in repair and scarring processes following injuries and 
inflammation (Sarafian et al.). Pericytes secrete growth factors which are important for 
maturation and remodeling of vascular system. They are involved in transport across BBB 
and regulation of vascular permeability  (Allt and Lawrenson, 2001).  
Blood-Cerebrospinal Fluid Barrier (BCSFB) 
The BCSFB is another barrier which restricts entry of systemically administered 
drugs into CNS. BCSFB functions in conjunction with BBB and meninges to safeguard 
brain. CSF is secreted from choroid plexus epithelium (CPE) and circulates through 
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ventricles around brain and spinal cord (Engelhardt and Sorokin, 2009). Choroid plexus (CP) 
are villous structures floating in cerebrospinal fluid and attached to ventricular ependyma. 
The ependyma is continuous with the epithelial layer of CP composed of single layer of cells. 
These CPE cells constitute BCSFB (Abbott et al.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the blood–brain barrier (BBB) 
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Tight junctions are present in CP epithelium restricting solute transport. Tight junctions on 
BCSFB are distinct and exhibit less restriction to diffusion of solutes in comparison with 
BBB  (Johanson et al., 2005). In addition to TJs, CP epithelium is fortified with organic acid 
transporter system which is responsible for driving organic acids in CSF to blood. Hence 
variety of therapeutic organic acids, such as zidovudine, methotrexate and penicillin, cannot 
gain access to brain parenchyma. Arachnoid epithelium serves as another barrier for transport 
of drugs in to the brain. Arachnoid is one of the three meninges, underlying dura, covers 
entire CNS as a protective sheath and separates extracellular fluids of CNS from rest of the 
body (Abbott et al.; Abbott, 2002). However, low surface area and avascular nature of 
arachnoid makes it less significant interface for solute exchange from blood to CNS (Abbott, 
2005). All these barriers form a combination of physical, transport and metabolic barriers 
resulting in restricted environment for solute entry into brain. Various approaches have been 
attempted for improving brain permeation of drugs. Some of the common approaches have 
been discussed in the following sections. 
ABC Efflux Transporters 
 
The ABC super family is one of the 16 subfamilies that are driven by ATP. There are 
seven subfamilies classified as ABC transporters (ABCA – ABCG). This family includes 
clinically significant MDR pumps, P-gp and MRP, all of which confer resistance to 
anticancer drugs. Remaining transporters are mainly expressed in a number of pathogenic 
fungi and parasitic protozoa, where they confer resistance to antimicrobial drugs (Legare et 
al., 2001). Although, most ABC proteins were discovered as drug transporters, these proteins 
frequently translocate a wide range of substrates, including dyes, ionophoric peptides, lipids 
and steroids. Members of the ABC family share extensive homology and domain 
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organization. The general structure of ABC transporters is composed of two homologous 
halves, each containing six putative transmembrane domains (TMDs) and an ATP-binding 
domain located towards the cytoplasm. There are a number of exceptions to this structural 
arrangement. For example, MRP1 – 3 and MRP6 – 7 have a third membrane spanning 
domain (MSD) with five TMDs (Bakos et al., 1996; Hipfner et al., 1997). BCRP, in 
comparison, is a half transporter (6) and is believed to dimerize in order for it to participate in 
transport activity that result in substrate tropism corresponding to different dimerization 
partners. Both nucleotide binding sites are necessary for the efflux of substrates (Urbatsch et 
al., 1995). 
P-glycoprotein (MDR1) 
P-glycoprotein (P-gp) is a 170–kDa phosphorylated and glycosylated plasma 
membrane protein belonging to the ABC super family of transport proteins encoded by 
MDR. P-gp was discovered by Juliano and Ling in 1970s and is the most widely studied 
efflux transporter till date (Juliano and Ling, 1976). This ABC transporter has been proposed 
to act as a “hydrophobic vacuum cleaner” because of its ability to remove lipids as well as 
drug molecules from intracellular environment. It is the primary active drug efflux pump 
which binds and translocates molecules against a concentration gradient at an expense of 
ATP hydrolysis (Katragadda et al., 2005).  
The most striking property of P-gp is its broad substrate specificity. Substrates of P-
gp include anticancer agent, H2-receptor antagonists, HIV protease inhibitors, antibiotics, 
anti-hypertensives, steroids, linear and cyclic peptides, calcium channel blockers, corticoids 
and immunosuppressive agents (Schinkel and Jonker, 2003). P-gp plays a major role in drug 
disposition by limiting the absorption and accumulation of xenobiotics and conferring 
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resistance to a diverse range of compounds. P-gp expression has been documented in a wide 
range of normal tissues like kidney, adrenal gland, liver, small intestine, colon, lung, prostate, 
skin, spleen, placenta, heart, skeletal muscle, stomach, blood brain barrier (BBB), and ovary 
(Ambudkar et al., 2003). P-gp is predominantly expressed on apical membrane of lower GI 
tract, brain, testis and kidney. Its constitutive expression in wide range of tissues suggests its 
role as a barrier to xenobiotic entry into the cells (Thiebaut et al., 1987; Cordon-Cardo et al., 
1989).  
P-gp on Intestinal Epithelium 
In humans, P-gp is highly expressed on the apical surface of superficial columnar 
epithelial cells of ileum and colon, and expression gradually decreases proximally into the 
jejunum, duodenum, and stomach (Ho et al., 2003). It is extensively localized on the villus 
tip of enterocytes which is the main site for absorption of orally administered drugs. 
Involvement of P-gp in drug absorption was first demonstrated in vitro with Caco-2 cells 
(Hunter et al., 1993). Later, role of P-gp in pharmacological aspects was demonstrated in 
mdr1a(-/-) knockout mice (Sparreboom et al., 1997). The results obtained in this study 
demonstrated that paclitaxel following oral administration in mdr1a(-/-) knockout mice 
exhibited a six fold increase area under curve (AUC). Similar results were obtained with HIV 
protease inhibitors indinavir, nelfinavir and saquinavir (Kim et al., 1998). Intestinal 
absorption of vinblastine and acebutolol increased 2.2- and 2.6-fold, respectively, when co-
administered with cyclosporine, which is a known P-gp inhibitor (Terao et al., 1996).  These 
results clearly indicate the role of P-gp in oral absorption of various therapeutic agents.  
 
 
22 
 
P-gp at the Blood–Brain Barrier 
High level of P-gp is expressed on luminal side of brain endothelial cells (i.e., facing 
blood side) (Cordon-Cardo et al., 1989). Therapeutic agents which are substrates of P-gp 
trying to enter the endothelial cells from the blood side are effluxed out immediately, 
blocking their entry into brain parenchymal cells. HIV protease inhibitors represent one of 
the most potent therapeutic classes developed so far for the treatment of HIV. However, 
being the substrates of P-gp, these compounds are poorly transported across BBB. As a 
result, success rate in treating HIV-related dementia is on the lower side (Golden and 
Pollack, 2003). Treatment failure in many CNS diseases, including Alzheimer’s disease, 
multiple sclerosis and Parkinson’s is primarily due to low brain uptake of therapeutic agents 
(Vogelgesang et al., 2004). Several studies have shown that the P-gp expression on the BBB 
restricts the entry of HIV-1 protease inhibitors into the brain (Edwards et al., 2002; Park and 
Sinko, 2005). Recent studies in multidrug resistant-1a (MDR-1a) knockout mice 
demonstrated increased levels of protease inhibitors in mouse brain (Washington et al., 2000; 
Salama et al., 2005). Thus, P-gp expression plays a major role in the disposition of the drugs 
across the BBB. Better drug delivery strategies bypassing P-gp mediated efflux and 
improving brain concentration of PIs, are essential to improve drug efficacy and lower 
treatment failure. Several strategies have been developed to inhibit or bypass P-gp mediated 
efflux.  Various P-gp inhibitors are often co-administered with P-gp substrates (therapeutic 
agents) resulting in higher bioavailability (Tolcher et al., 1996). However, systemic 
administration of P-gp inhibitors is limited by their toxicity resulting from high doses 
required to inhibit P-gp in-vivo. Although various approaches have been explored to 
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overcome P-gp mediated drug efflux, P-gp still remains a major barrier to oral and CNS drug 
absorption. 
Multidrug Resistance Associated Proteins (MRPs) 
RP family contains at least nine members: MRP-1 and its eight homologs, known as 
MRP2-9.These membrane proteins mediate the ATP-dependent unidirectional efflux of 
glutathione, glucuronate, or sulfate conjugates of lipophilic drugs.  In addition to many 
anionic conjugates, a number of unconjugated amphiphilic anions can serve as substrates for 
MRPs. Recent reports have identified MRP in the brain capillary endothelium and human 
brain microvessels. Of the nine MRP isoforms currently identified, a recent report identified 
MRP homologues MRP1, MRP4, MRP5, and MRP6 in both primary cultured bovine brain 
endothelial cells and capillary-enriched bovine brain homogenates. MRP7 has been identified 
in brain homogenate, but its exact localization has not been determined. MRP-2 has been 
identified in the apical (luminal) membrane of rat brain capillary endothelium (Miller et al., 
2000). Expression of various isoforms of MRP and other efflux proteins is shown in Figure 
4.   
 
 
 
Figure 4. Vairous efflux proteins expressed on brain capillary endothelial cells. Reproduced with 
permission (W Lösche et al., 2005) 
) 
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Recent studies revealed that MRPs play a significant role in-vivo in the absorption of 
saquinavir across BBB (Park and Sinko, 2005). However various literature reports suggest 
that APV is not a very good substrate of MRP1 and has little interaction with MRPs (van der 
Sandt et al., 2001). 
Plasma Protein Binding 
The pharmacokinetic and pharmacodynamic properties of drugs are largely a function 
of the reversible binding of drugs to plasma or serum proteins. Plasma proteins include 
albumin, α1-acid glycoprotein (AAG), lipoproteins and α, β and γ globulins (Huang and Ung; 
Kremer et al., 1988). Generally, the unbound drug is available for diffusion or transport 
across cell membranes, and for interaction with pharmacological targets (e.g. receptor, ion 
channel, transporter, and enzyme) (Rowland, 1984). Plasma protein binding of a drug also 
influences its distribution, elimination, and drug action. Highly plasma protein bound drugs 
are confined to the vascular space, resulting in low volume of distribution. In contrast, drugs 
that remain largely unbound in plasma are generally available for distribution to other organs 
including brain. Higher plasma protein binding of drugs is associated with low efficacy. Most 
HIV-protease inhibitors (PIs) bind to AAG. When tested in-vitro against wild type HIV, 
AAG is responsible for the decrease in activity of the current PIs exhibiting high plasma 
protein binding. Most PIs are highly bound to plasma proteins, nelfinavir (99% bound), 
lopinavir (99%), saquinavir (98%), ritonavir (98%), amprenavir (90%) and indinavir (60%) 
(Anderson et al., 2000; Boffito et al., 2003; Barrail et al., 2006). Determination of both total 
and unbound plasma drug concentrations is, therefore, necessary to assess drug availability 
and anti-HIV efficacy. Furthermore, an increase in unbound drug fraction may increase drug 
availability at the target site. 
25 
 
Metabolizing Enzymes  
Cytochrome P450 (CYP) is the most prevalent drug metabolizing enzymes and is 
present predominantly in the intestine and liver. CYP3A4 is the most abundant form in the 
CYP-family (Kolars et al., 1992). CYP3A group represents the major drug-metabolizing 
enzyme and accounts for approximately 30% of hepatic CYP and more than 70% of 
intestinal CYP activity. Moreover, CYP3A is estimated to metabolize between 50% and 70% 
of currently administered drugs (Watkins, 1997). CYP3A4 enzyme is present in the liver and 
enterocytes (Guengerich et al., 1986). A significant amount of CYP3A is expressed in the 
enterocytes to metabolize xenobiotics during their transit across intestinal epithelium. 
According to recent reports, CYP3A5 is also polymorphically expressed in small intestine 
and contributes significantly to drug metabolism (Shen et al., 1997). Although hepatic 
metabolism can make a major contribution to systemic drug elimination, a combination of 
hepatic and intestinal drug metabolism appears to have a major influence on pre-systemic or 
first-pass drug loss. CYP3A4 has wide substrate specificity. It can metabolize various 
structurally diverse therapeutic agents. CYP3A4 and P-gp have a considerable overlap in 
substrate specificity and tissue distribution. Which may further reduces the drug 
concentration in blood affecting drug bioavailability and therapeutic efficacy. For drugs 
which are common substrates of P-gp and CYP3A4, such as HIV PIs, P-gp efflux increases 
drug exposure to CYP3A4 in the intestinal lumen which leads to more extensive metabolism 
by CYP3A4 (Watkins, 1997; Benet and Cummins, 2001). The metabolism of xenobiotics via 
phase I functionalization and phase II conjugation converts drugs to water soluble 
metabolites which can be excreted from the body and reduce the potential toxicity. Although 
the ultimate elimination of the parent drug and its metabolites from the body is necessary, the 
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extensive early-stage metabolic processing of orally administrated drugs is undesirable since 
the drug concentration in system circulation and targeted tissues cannot reach the therapeutic 
level. 
Amprenavir undergoes extensive first pass metabolism by CYP3A4. Ketoconazole 
(selective CYP3A4 inhibitor) inhibited the formation of major amprenavir metabolites. 3.7 
µM of ritonavir completely inhibited the biotransformation of amprenavir by human liver 
microsomes (Treluyer et al., 2003). Metabolism of ritonavir, on the other hand, is caused by 
CYP3A4 and CYP2D6. It significantly inhibits the metabolism of CYP3A4 substrates like 
nifedipine and CYP2D6 substrates like dextromethorphan, when administered in 
combination (Hsu et al., 1998). In addition to oxidative metabolism, conjugation reactions 
may play an important role in detoxification of xenobiotics from the small intestine. Specific 
molecules are effluxed into intestinal lumen after being conjugated with a glucuronide or 
sulfate moiety within enterocytes. Transport systems responsible for the cellular efflux of the 
conjugated metabolites and organic anions have been characterized recently (Leslie et al., 
2001). 
Strategies to Overcome P-gp and MRP Mediated Efflux 
Developing drug strategies to circumvent P-gp and MRP mediated efflux is an unmet 
need in drug delivery. Designing drug molecules with no interaction with these efflux pumps 
is limited due to the fact that modification of drug molecule can result in loss of potency and 
biological stability. Another challenge for designing effective drug molecules is that till date 
3D crystal structure of P-gp and MRP is not elucidated and poorly understood. However, 
some of the strategies have been adopted that have resulted in partial of full circumvention of 
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P-gp and MRP mediated efflux. Some of those strategies are discussed in the following 
paragraphs. 
Various approaches have been studied by researchers to circumvent P-gp mediated 
efflux and first –pass metabolism there by to improve oral bioavailability of poorly absorbed 
drugs. One of the approaches is co-administration of P-gp and/or CYP3A4 modulators or 
inhibitors to inhibit the function of P-gp and/or CYP3A4 (Eagling et al., 1999; Patel and 
Mitra, 2001). Some of the inhibitors/modulators are laniquidar (R101933), ocl44-093 (ONT-
093), zosuquidar (LY335979), elacridar (GF-120918) and tariquidar (XR9576). Although 
this approach result in higher bioavailability, success of this approach is hindered by side 
effects due to alteration of normal physiological roles of these proteins and increasing the 
cytotoxicity due to the high doses required to inhibit the functions of these proteins. 
Synthesis of lipophilic ester prodrugs to enhance transport across epithelial cells constitutes 
one such strategy (Chang et al., 1987). Although this approach has been successful to some 
extent, lowered aqueous solubility of these modified compounds often proves to be a 
challenge in the development of orally bioavailable dosage forms. Other strategies to 
enhance drug absorption from the intestine include the formulation of nanospheres and 
microspheres (Hodges et al., 1995; Thomas et al., 1996). Application of polymers which 
transiently perturb the tight junctions between epithelial cells is another approach (Kotze et 
al., 1998; Dorkoosh et al., 2004). However, to date, these approaches have met with limited 
success. Membrane fluidizing agents and penetration enhancers have also been investigated 
(Shao et al., 1994). However, cellular toxicities have, for the most part, limited their use. 
Prodrugs targeted towards membrane transporters expressed on epithelial cells are perhaps 
the most exciting of all the current drug delivery strategies (Anand et al., 2002). 
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Pro-drug (PD) and Pro-Pro-Drug (PPD) Approach 
 The unfavorable physicochemical properties such as low aqueous solubility and 
physiological properties such as substrate for efflux proteins, high CYP3A4 metabolism and 
high protein biding attribute to low bioavailability of PIs (Watkins, 1997; Wacher et al., 
1998). The presence of efflux transporter (P-gp, MRP) imposes a major obstacle for the entry 
of PIs across the intestinal epithelium and BBB. Co-administration of several agents that are 
P-gp substrates/inhibitors are often employed to improve permeability characteristics of these 
agents. However, lack of specificity and high concentrations required to inhibit efflux 
process often results in unacceptable toxicities and limits their usefulness. This co-
administration may also affect the physiological function of efflux proteins and may lead to 
related toxicities. Potentially promising approach to improve oral bioavailability and brain 
permeation of PIs is by circumventing efflux transporters at both intestinal epithelium and 
BBB. Prodrug seems a viable approach for improving brain bioavailability of PIs. We 
propose to develop amino acid and di-peptide conjugated prodrugs of HIV PIs and we 
hypothesize that the resultant prodrugs will generate enhanced brain bioavailability. The 
ligand coupled PIs will permeate brain capillary endothelial cells efficiently by binding and 
translocating via influx membrane transporters and bypass membrane efflux pumps like P-gp 
and MRPs. The approach is depicted in Figure 5, where a drug, which is a substrate for an 
efflux transporter, is converted to a substrate of a targeted influx transporter (amino acid, 
peptide and vitamin) by coupling to a pro moiety. The resultant prodrug is not recognized by 
the efflux transporters and is ferried across the membrane. We named di-peptide prodrug as 
pro-pro-drug (PPD), each “pro” representing an amino acid promoiety. In the pro-pro-drug 
strategy, following oral administration of pro-pro-drug (di-peptide conjugated drug) may 
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evade the efflux at intestinal epithelium and circumvent the efflux. By circumvention of 
efflux, pro-pro-drug exposure to metabolizing enzymes in the intestinal lumen will be 
minimized. Once the di-peptide prodrug reaches systemic circulation, PPD may undergo 
enzymatic degradation and generate PD and some amount of drug (Figure.6). Systemically 
generated PD can be identified by nutrient transporters expressed on BBB and circumvent 
the efflux. This may lead to enhanced permeation across BBB. Major advantage of this PPD 
approach is to be able to target two nutrient transporters expressed on two different barriers. 
Design of PPDs targeting such active transport processes represents paradigm shift from the 
traditional prodrug approach. The nutrient transporters described in the following sections 
will be targeted for this purpose. 
Nutrient Transported to be Targeted 
Various nutrient transporters apart from efflux transporters are expressed on epithelial 
(intestinal) and endothelial (brain vascular endothelial) cells these influx transporters are 
responsible for active transport of various nutrients such as amino acids, peptides and 
vitamins. Intestinal peptide transporter and amino acid transporters are targeted in this 
project. Expression pattern of these transporters and functionality are discussed in the 
following section.  
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Figure 5. Circumvention of membrane efflux by prodrug derivatization 
targeting influx transporters 
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Figure 6. Hypothetical mechanisms involved in pro-pro-drug 
approach to improve oral and brain bioavailability 
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Peptide Transporter System 
Peptide transporters are the most versatile proteins available for drug transport. 
Belonging to peptide transporter (PTR) family, it serves as an integral membrane protein 
especially in the intestinal membrane to accept various di- and tri-peptides as substrates, 
thereby acting as both nutrient and drug transporter (Terada and Inui, 2004; Rubio-Aliaga 
and Daniel, 2008). Peptide transporter or PEPT as it is commonly referred to, is a solute 
carrier protein and is classified into two broad classes: PEPT1 (SLC15A1) and PEPT2 
(SLC15A2), differing in their tissue localization, substrate specificity, affinity as well as 
transporter capacity (Rubio-Aliaga and Daniel, 2002). Both PEPT1 and PEPT2 are highly 
expressed in various epithelia however, PEPT1 is involved in translocation of di- and tri-
peptides and peptidomimetic analogues in the small intestine whereas PEPT2 is primarily 
localized on the renal tubular epithelium (Rubio-Aliaga and Daniel, 2008). These 
transporters are also found in other tissues such as brain, lungs, bile duct and pancreas 
(Rubio-Aliaga and Daniel, 2002). In addition to peptide transporters, PTR family also 
consists of two peptide histidine transporters, namely PHT1 and PHT2, involved in 
specifically translocating histidine and a few selected di- and tri-peptides (Rubio-Aliaga and 
Daniel, 2008). Not much work has been reported on PHTs; however, PEPT has gained a lot 
of attention recently as a drug delivery target. Intestinal PEPT not only provides uptake of di- 
and tri-peptides, but also functions as a possible vehicle site for the delivery of 
pharmacologically active peptidomimetics i.e. β-lactam antibiotics, ACE inhibitors, bestatin, 
thrombin inhibitors and rennin inhibitors (Yang et al., 1999; Rubio-Aliaga and Daniel, 2008). 
Both PEPT1 and PEPT2 are considered an ideal target for drug delivery because of its high 
capacity and affinity towards di- and tri-peptide moieties. Therefore, if a drug exhibits low 
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oral bioavailability such as acyclovir and ganciclovir, conjugation with a moiety which is 
easily recognizable by the transporter makes the adduct a substrate for the transporter. This 
prodrug, in other words, can be defined as a derivatized drug which is a substrate for the 
influx transporter, in this case PEPT. Thus derivatization of the drug molecule allows the 
newly formed substrate to be ferried across the lipid bilayer membrane. Physico-chemical 
property such as water solubility is also improved based on the amino acid chosen for 
derivatizing the drug. Once the di-peptide prodrug is translocated across the intestinal lipid 
bilayer utilizing the PEPT, it is broken down into amino acid prodrug by peptidases. The 
newly generated amino acid intermediate then reaches the target tissue such as brain utilizing 
the amino acid transporter for permeation. Since peptide transporters are robust and high 
capacity transporters, their utilization to ferry the prodrugs of PIs across the physiological 
barriers may prove to be a highly effective strategy (Yang et al., 2001). 
Amino Acid Transport Systems 
Amino acid transporters are present in all mammalian cells and translocate nutrient 
amino acids. Final steps in biotransformation of proteins result in the formation of di/tri 
peptides and amino acids, while translocation of these di/tri peptides involves a peptide 
transporter (PepT1), absorption of amino acids involves several transport systems. Amino 
acid transport systems are mainly classified according to sodium ion dependency and 
substrate specificity. These transport systems are broadly divided into Zwitterionic, Cationic 
and Anionic amino acid transporters. Due to the presence of multiple transport systems and 
overlapping substrate specificities, transport of amino acids across a cell membrane is a 
highly complex phenomenon. Depending upon the capacity and affinity, amino acid 
transporters can move not only naturally occurring amino acids but also structurally related 
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compounds such as antiparkinsonian agent L-Dopa, anticancer agent melphalan, thyroid 
hormones and gabapentin (Goldenberg et al., 1979; Su et al., 1995). These findings implicate 
that amino acid transport system could be utilized as a potential drug delivery tool to enhance 
the bio-availability of poorly permeable drug molecules. Small neutral amino acids are 
transported predominantly by Na+ dependent transport system such as ASC (for Ala-, Ser-, 
and Cys-preferring), system A (for Ala-preferring) & B0,+ (neutral and cationic amino acids 
preferring) and Na+-independent transport system ASC, LAT (large neutral amino acids 
preferring) and b0,+. Systems, b0,+, y+L and B0,+ translocate a wide range of substrates, 
including cationic and neutral amino acids, differing however in their interactions with 
inorganic monovalent ions such as Na+.  
Due to their Localization on a variety of tissues including intestinal, nasal and BBB 
amino acids transporters may prove to be a useful target in transporter targeted drug delivery  
(Hundal and Taylor, 2009). Currently, nine amino acid transport systems (Figure 7) have 
been reported to be present at the brain capillary endothelium of the BBB (Smith, 2000). 
Among these types, large neutral amino acid transporter, system L, and cationic amino acid 
transporter, system y+, are present on the BBB as Na+ independent systems. Similarly, Na+ 
dependent amino acid transporter such as system x-, neutral and/or cationic amino acid 
transporters, system A, BO+, and ASC, and a beta-amino acid systems are also known to be 
present on the BBB. Among these types, system L has broad substrate specificity for 
relatively large neutral amino acids such as phenylalanine, tyrosine, leucine and is known to 
transport CNS acting drugs such as L-dopa, lacrofen and gabapentin (Tsuji and Tamai, 
1999). System x- transports anionic amino acids, such as aspartic acid and glutamic acid at 
BBB (Tamai and Tsuji, 2000). CAT-1 and CAT-2 were cloned as y+ transporters. Although 
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both of them are expressed in brain, only CAT-1 is present at BBB and mediates the 
transport of cationic amino acids like lysine, arginine and ornithine (Stoll et al., 1993). 
Presence of such a transport system can lead to the design of compounds, with enhanced 
permeability across the BBB.  
 
 
 
 
Figure 7. Various amino acid transport systems expressed 
on BBB (Smith, 2000) 
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CHAPTER 3 
CIRCUMVENTION OF P-GP MEDIATED EFFLUX AND ENHANCING 
PERMEABILITY OF AMPRENAVIR BY PRODRUG DERIVATIZATION  
Rationale 
Current drug therapy for HIV-infected patients usually consists of a combination of 
HIV protease inhibitors and nucleoside reverse transcriptase inhibitors, which has resulted in 
a dramatic reduction of viral load in plasma and many tissues of infected patients (Conway et 
al., 1998). Although both classes of drug are potent agents in the therapy of HIV infection, 
combination therapy is more effective than the use of only one class of drug (Gulick et al., 
1997; Cameron et al., 1998). Protease inhibitors (PIs) have been an important constituent of 
‘highly active anti-retroviral therapy’ (HAART) which has substantially improved clinical 
outcomes of AIDS patients. However, complete eradication of HIV infection still remains an 
elusive goal. Sub-therapeutic concentrations of PIs in the sanctuary sites like brain, lung and 
bone-marrow cause persistent viral infection and may lead to viral resistance. One of the 
factors that may limit therapeutic efficacy of PIs is cellular efflux mediated by proteins like 
P-glycoprotein (P-gp) (Kim et al., 1998). 
Amprenavir (APV) belongs to PIs and is an orally active nonpeptide inhibitor of the 
HIV aspartic protease enzyme. This enzyme plays an essential role in the post-translational 
processing of the gag and gag-pol gene products into key structural proteins and replication 
enzymes of HIV. Inhibition of HIV protease, therefore, results in the inhibition of processes 
necessary for viral maturation and proliferation (Moyle and Gazzard, 1996). Despite of good 
antiviral efficacy, APV suffers from low oral and brain bioavailability. APV exhibits low 
oral bioavailability, about 14-26%. APV like other PIs is a substrate of efflux protein, P-gp 
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and extensively metabolized by CYP3A4 (van der Sandt et al., 2001; Tran et al., 2005; 
Acharya et al., 2006). These reasons attribute to low oral bioavailability of APV. Hence APV 
is administered in combination with other PIs or NRTIs. One of the major factors limiting 
low oral absorption is cellular efflux mediated by P-glycoprotein (P-gp). P-gp is 170 kDa 
membrane bound protein highly expressed on intestinal epithelium. P-gp is localized at villus 
tip of enterocytes, main site for drug absorption, and effluxes drugs back into intestinal 
epithelium limiting oral absorption and ultimately low therapeutic efficacy (Jain et al., 2005; 
Agarwal et al., 2008).  Various approaches have been attempted to improve oral absorption 
of drugs which are P-gp substrates. For example co-administration of P-gp inhibitors along 
with P-gp substrates, modulating expression of efflux proteins and chemical modification of 
drugs such that efflux can be evaded (Agarwal et al., 2008). Modulating P-gp expression or 
co-administration of high doses of P-gp inhibitors may lead to systemic toxicities by 
inhibiting physiological function of efflux proteins. Chemical modification of molecules such 
as prodrug approaches have an advantage of evading efflux without affecting physiological 
function of efflux proteins. Moreover evasion of efflux will also minimize drug exposure to 
metabolizing enzymes in intestinal lumen (Jain et al., 2005). Apart from efflux proteins, 
various nutrient transporters are also expressed on cell membranes of intestinal epithelium 
and BBB. These nutrient influx transporters are responsible for transport of nutrients across 
cells. Peptide and amino acid transport systems on intestinal epithelial cells are well 
established. Among the nutrient transporters, peptide transporters serve as promising targets 
due to their broad substrate specificity and high capacity. Peptide transporter targeted 
prodrug approach has been well established (Jain et al., 2007; Jain et al., 2008; Talluri et al., 
2008). Prodrugs designed such that they can evade efflux by P-gp and utilize peptide 
38 
 
transporter for translocating across intestinal epithelium, may exhibit better absorption and 
improved bioavailability. Hence the objective of present study is to investigate the feasibility 
of evading efflux and enhance permeability of APV by prodrug derivatization. Di-peptide 
prodrugs of APV have been synthesized. Based on the previous publications L-Val-L-Val 
and L-Gly-L-Val exhibited better affinity for peptide transporter, hence were chosen as 
promoities and di-peptide prodrugs of APV were synthesized. Aqueous solubility of the 
prodrugs was determined. Cytotoxicity studies were performed in MDCKII-WT cells.  In 
order to study interaction of these prodrugs with both efflux and influx transporters, 
MDCKII-MDR1 cells were employed. MDCKII-MDR1 cell line is genetically engineered to 
overexpress P-gp and well established model to study drug-transporter interactions. Cellular 
accumulation and bi-directional transport studies were performed.   
Materials and Methods 
Materials 
Unlabeled (ulb) amprenavir (APV) and P-gp inhibitor, GF120918 (GF), were 
generous gifts from GlaxoSmithKline Ltd., respectively. [3H]glycylsarcosine (3H-GS) (4 
Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA, USA). MK-571 (MK) was 
purchased from Biomol (Plymouth Meeting, PA, USA). HPLC grade DMSO and methanol 
were obtained from Fisher Scientific Co. (Pittsburgh, PA, USA). These solvents were used 
neat for preparing stock solutions of all drugs and inhibitors. Trypsin–EDTA solution, 
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Invitrogen (Carlsbad, 
CA, USA) and fetal bovine serum (FBS) was obtained from Atlanta Biologicals 
(Lawrenceville,GA,USA). Transwell® inserts and uptake plates were procured from Corning 
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Costar Corp. (Cambridge, MA, USA). All other chemicals were of analytical reagent grade 
and were obtained from Fisher Scientific or Sigma Chemicals. 
Methods 
Cell Culture 
Studies were performed with stable Madin-Darby canine kidney cells type II 
transfectants overexpressing hP-gp/MDR1 (MDCKII-MDR1 cells; passages 5 to 15); 
hMRP2 (MDCKII-MRP2 cells; passages 5 to 25) ; and wild type MDCKII cells generously 
provided by Drs. A. Schinkel and P. Borst, The Netherlands Cancer Institute, Amsterdam. 
These cell lines were cultured in T-75 flasks with DMEM (with high glucose and glutamine 
concentrations) supplemented with 10% FBS, 1% nonessential amino acids, penicillin 
100µg/mL and streptomycin 100U/mL. The medium was changed every alternate day; cells 
were harvested and passaged via trypsinization at 80 to 90% confluence (about 4 days of 
growth). Cells were also grown on collagen coated Transwell® inserts (12-mm) with 
transparent polyester membranes. Transwell® inserts were coated with type 1 rat tail collagen 
(100µg/cm2), equilibrated with medium, and seeded at a 25,000 cells/cm2 density. Following 
seeding, medium was changed every alternate day, and transport or uptake studies were 
performed after incubation of 5-7 days. 
Solubility Studies  
Solubilities of the prodrugs were determined in distilled deionized water (DDW). 
Saturated drug solutions were prepared in silicone coated microcentrifuge tubes and kept at 
room temperature for 24h in a shaker bath. At the end of 24h, the undissolved drug was 
removed by ultracentrifugation at 25000g for 5min. The supernatant was appropriately 
diluted and drug concentration was measured with LC/MS/MS. 
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Buffer Stability Studies 
 Hydrolytic Stability of prodrugs was determined at various pH values. 
Buffers, HCl (pH 1.4), phthalate (pH 3.4 and 5.4), phosphate (pH 7.4), and boric acid (pH 
9.4), were prepared and ionic strength was adjusted to 0.1M. The buffer strength was also 
adjusted to 50 mM for all the buffers. Stock solutions of prodrugs (0.5-1 mg/mL) were 
prepared in methanol and used immediately for stability studies. Aliquots (9.8 mL) of the 
buffer were placed in screw capped vials and allowed to equilibrate at 37°C. Prodrug stock 
solution containing 50 µg of prodrug (0.1 to 0.05 mL) was subsequently added to the buffer 
and vials were placed in a water bath maintained at 37°C and rotated at 60 rpm. Samples (0.2 
mL) were collected at appropriate time interval for up to 7 days. Samples were immediately 
stored at -80°C until further analysis. All experiments were conducted at least in triplicate. 
Cytotoxicity Studies 
Cytotoxicity of the prodrugs was determined in MDCKII-WT cells using an aqueous 
non-radioactive cytotoxicity kit based on the MTS assay. The assay determines cell viability 
based on the mitochondrial conversion of a water-soluble tetrazolium salt [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolum bromide; MTT] to the water-insoluble blue 
formazan product. The cytotoxicity kit is supplied as a salt solution of MTT (known as MTS) 
with an electron coupling reagent PMS (phenazine methosulfate). PMS has enhanced 
chemical stability, which allows it to be combined with MTS to form a stable solution 
eliminating the need to solubilize formazan crystals using an external source. Briefly, cells 
were grown in 96 well tissue culture plates at 10,000 cells per well for 24h prior to drug 
treatment. Culture medium was then replaced with 100μl of medium containing serial 
dilutions of the prodrugs (5-250μM). Cells were then incubated for 4h at 37°C under 5% 
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CO2. After the treatment period was over, 20μl of MTS stock solution was added to each 
well. After addition of the MTS dye, the cells were incubated for 2h at 37°C. Cell viability 
was then assessed by measuring absorbance at 485nm on an automated plate reader (Biorad, 
Hercules, CA). The quantity of formazan product as measured by the amount of 485nm 
absorbance is directly proportional to the number of living cells in culture. 
Uptake Studies 
Uptake studies were conducted with confluent cell monolayers, 5-7 days post seeding 
for MDCKII cells. Medium was aspirated and cells were washed three times with DPBS. All 
drug solutions were prepared immediately prior to an experiment. The study was initiated by 
adding 1mL of drug solution (in the presence or absence of competing substrates) to the 
wells. Incubation was carried out over a period of 15min at 37°C. At the end of an incubation 
period, drug solution was removed and the cell monolayer was washed three times with ice-
cold ice-cold PBS. Cells were lysed overnight with 1mL 0.1% (w/v) Triton X-100 in 0.3N 
sodium hydroxide at room temperature. Aliquots (500µL) were withdrawn from each well 
and transferred to vials containing 5mL scintillation cocktail. Samples were then analyzed 
with a Beckman scintillation counter (Model LS-6500, Beckman Instruments, Inc.). Uptake 
was normalized to the protein content of each well. Amount of protein in the cell lysate was 
quantified by the method of Bradford utilizing BioRad protein estimation kit (BioRad, 
Hercules, CA).  
Transport Studies  
APV transport was evaluated with monolayers of MDCKII-MDR1 cell line. All 
transport studies were performed with Dulbecco’s modified phosphate-buffered saline 
(DPBS) containing glucose (1g/L) and HEPES (20mM) at pH 7.4. Drug solutions were 
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prepared immediately prior to initiating a transport study. APV and prodrugs (VA,VVA and 
GVA) were dissolved in methanol (not exceeding 2% v/v as the final concentration) and 
inhibitors were separately dissolved in DMSO (not exceeding 2% v/v as the final 
concentration) to prepare a stock solution and then diluted with DPBS to the specified final 
concentrations. Control solutions contained the same amount of methanol/DMSO as the drug 
solutions. Volumes of test solutions added were 0.5 and 1.5mL, for apical (A) and basolateral 
(B) chambers respectively. Prior to initiating an experiment, cultured monolayers were rinsed 
and equilibrated for 30min with DPBS. Drug solution was added either in the donor or 
receiving chamber for A to B and B to A transport study. Samples (100µL) were withdrawn 
from the receiving chamber at predetermined time points (15, 30, 60, 90, 120, 150, 180) and 
were replaced with equal volume of DPBS to maintain sink conditions. Dilutions were taken 
into account for the calculations. Samples were stored at −80˚C until further analysis. All the 
experiments were performed at 37˚C in triplicate.  
Sample Preparation 
Uptake and transport study samples were analyzed with LC/MS/MS. Sample 
preparation was carried out using liquid-liquid extraction technique.  Verapamil was 
employed as an internal standard (IS) for analysis. The organic solvent, methyl- tert-butyl 
ether was utilized to extract the drug from the aqueous phase. Briefly, 50l of IS was added 
to the transport sample (100l). Each sample was mixed with 500l of organic solvent. All 
samples were vortexed again for 1-2min to allow enough time for the drug to partition into 
the organic phase. For efficient separation of the aqueous and organic layers, samples were 
centrifuged at 25000g for 5min and then were stored at -20ºC for sufficient time to allow 
freezing of the aqueous layer. The organic layer was decanted and samples were dried in 
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vacuum.  The residue was reconstituted in 100l of 70:30 acetonitrile: DDW and 0.1% 
formic acid to allow efficient solubilization of the dried drug. This reconstituted extract was 
injected onto the LC/MS/MS for analysis. Standard solutions in buffer were also extracted 
and quantified exactly following the same procedure. Relative extraction efficiency (ratio of 
area for analyte VS area for IS) for APV, VA, VVA and GVA was approximately 50-70%. 
HPLC Analysis 
Buffer stability samples were analyzed by a reversed phase HPLC technique. The 
HPLC system was comprised of HP 1050 pump, Waters dual wavelength absorbance UV 
detector, and an Alcott auto sampler (model 718AL HPLC). A C(12) Lima column (250 x 
4.6mm; Phenomenex, Torrance, CA) was employed for the separation of analytes. Mobile 
phase composed of 50mM phosphate buffer: methanol: acetonitrile (39:22:39%; v/v/v) and 
the pH was adjusted to 5.9 with ortho-ophosphoric acid. Flow rate was maintained at 
0.8mL/min and detection wavelength was set at 215nm. Elution times for APV, V-APV, VV-
APV and for GV-APV were 6,8,16, 14 and 12 minutes respectively. 
LC/MS/MS Analysis 
QTrap LC/MS/MS mass spectrometer (Applied Biosystems, Foster City, CA, USA) 
equipped with Agilent 1100 Series quaternary pump (Agilent G1311A), vacuum degasser 
(Agilent G1379A) and autosampler (Agilent G1367A, Agilent Technology Inc., Palo Alto, 
CA, USA) was employed to analyze samples from transport and metabolism studies. HPLC 
separation was performed on reverse phase XTerra® MS C18 column with dimensions of 4.6 
x 50 mm and particle size of 5 µm. Mobile phase (70% acetonitrile and 30% water 
containing 0.1% formic acid) was continuously pumped through the column at a constant 
flow rate of 0.2 mL/min. The sample (20μl) was injected.  Electrospray ionization in the 
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positive mode was employed in the sample introduction. The detection was operated in 
multiple-reaction monitoring (MRM) mode. Precursor ion of analytes and internal standard 
were determined from spectra obtained during the infusion of standard solutions using an 
infusion pump connected directly to the electrospray source. As a result of the very soft 
ionization provided by the electrospray ion source, only singly charged molecular ions were 
observed.  Each of these precursor ions was subjected to collision-induced dissociation to 
determine the secondary ions. The precursor and the secondary ions generated were; APV + 
506.3/155.9; VVA + 704.4/156.1; GVA + 662.4/156.0; VA + 605.4/156.0 and Verapamil 
(IS) + 455.3/165.1. The turbo ion spray setting and collision gas pressure were optimized (IS 
Voltage: 5500V, temperature: 300°C, nebulizer gas: 40psi, curtain gas: 40psi). MS/MS was 
performed using nitrogen as collision gas. Other ion source parameters employed were: 
declustering potential (DP): 50V; collision energy (CE): 70V; entrance potential (EP) 5V; 
and collision cell exit potential (CXP) 3V. Peak areas for all components were automatically 
integrated by using Analyst™ software, and peak-area ratios (area for analyte VS area for IS) 
were plotted vs. concentration by weighted linear regression (1 VS concentration). The 
analytical data resulting from prodrugs with MRM method show a significant linearity that 
extends to nmol range. The limits of quantification were found to be 10 ng/mL for APV and 
50 ng/mL for VA, VVA and GVA. This method gave rapid and reproducible results. 
Data Analysis 
Cumulative amounts of prodrugs (VVA or GVA), the intermediate VA and the parent 
drug APV, generated during transport across the cell monolayers were plotted as a function 
of time to determine permeability coefficients. Linear regression of the amounts transported 
as a function of time yielded the rate of transport across the cell monolayer (dM/dt). Rate 
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divided by the cross-sectional area available for transport (A) generated the steady state flux 
as shown in Eq. 1. 
Flux=(dM/dt)/ A    Eq. 
1 
In all the transport studies, slopes obtained from the linear portion of the curve were used to 
calculate permeability values. Permeability was calculated by normalizing the steady state 
flux to the donor concentration (Cd) of the drug or prodrug as shown in Eq. 2.  
Permeability=Flux/Cd    Eq. 
2 
Statistical Analysis 
All experiments were conducted at least in triplicate and results are expressed as 
mean  S.D. Statistical comparison of mean values was performed with Student t test (Graph 
Pad INSTAT, version 3.1). A value of *P < 0.05 was considered to be statistically 
significant. 
Results and Discussion 
Synthesis and Identification of Prodrugs   
The synthesis of di-peptide prodrugs of APV involves conjugation of pro-moiety to 
the free hydroxyl group in APV. The carboxylic group of the amino acid or peptide can form 
the ester linkage with saquinavir which may improve the delivery of conjugated drug through 
transporters expressed on various tissues. There is an ester group between drug and 
immediate amino acid; an amide linkage between first amino acid and terminal amino acid. 
Both ester and peptide linkages are readily cleaved by esterases and peptidases present in 
tissues.  Steglich esterification was employed to synthesize the prodrugs. Overall synthetic 
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scheme for Valine-APV (VA), Valine-Valine-APV (VVA) and Glycine-Valine-APV (GVA) 
is described in Figure 8. 
Synthesis of Val-Amprenavir(4) 
 Commercially available BocVal-OH (429mg, 1.97mmol) was dissolved in dry DMF 
(10mL) and cooled it down to 0oC using ice bath. DCC (356mg, 1.72mmol) was added and 
stirred for 1h at same temperature. In a separate reaction flask Amprenavir (500mg, 
0.98mmol) was dissolved in DMF and add DMAP (120mg, 0.98mmol) and continued 
stirring for 10 min at room temperature under inert atmosphere to activate the secondary 
hydroxyl group of the Amprenavir(1). It was added in to the reaction mixture through a 
syringe and allowed it to come to the room temperature and continued stirring for 48h. Small 
portion of the reaction mixture was taken out and injected it in LC/MS to ensure the complete 
conversion of the starting material to product. Reaction mixture was filtered and solvent was 
evaporated at room temperature under reduced pressure to get crude product. The product 
Boc-Val-Amprenavir(3) was purified by silica column chromatography using 50% 
Ethylacetate/ Hexane as eluent with 93% yield. To deprotect the N-Boc Group, N-Boc-Val-
Amprenavir was treated with 80% TFA/ CH2Cl2 at 0
oC for 2.5h. The filtrates were 
evaporated in vacuo to constant weight. The crude products were purified by recrystallization 
from cold diethyl ether to get the final product Val-Amprenavir (4) with an excellent yield 
(98%). The prodrug was dried under vacuum for 10h before biological evaluation. 
Synthesis of Val-Val-Amprenavir (4) 
BocVal-Val-OH (187mg, 0.59mmol) was dissolved in dry DMF (5mL) and cooled it 
down to 0oC using ice bath. DCC (106mg, 0.51mmol) was added and stirred it for 1h at same 
temperature. In a separate reaction flask Amprenavir (150mg, 0.29mmol) was dissolved in 
47 
 
DMF and DMAP (37mg, 0.29mmol) was added followed by stirring for 10min at room 
temperature under inert atmosphere to activate the secondary hydroxyl group of the 
Amprenavir(1). This was added in to the reaction mixture through a syringe and allowed to 
come to the room temperature and stirring was continued for 48h. Small portion of the 
reaction mixture was taken out and injected it in LC/MS to ensure the complete conversion 
of the starting material to product. Reaction mixture was filtered and solvent was evaporated 
at room temperature under reduced pressure to get crude product. The product Boc-Val-Val-
Amprenavir (5) was purified by silica column chromatography using 50% Ethyl acetate/ 
Hexane as eluent with 87% yield. Val-Val-Amprenavir (6) was achieved after deprotection 
of the N-Boc group using TFA/ DCM (4:1) followed by recrystallization from cold diethyl 
ether. 
Synthesis of Gly-Val-Amprenavir (9) 
Commercially available BocGly-OH (163mg, 0.92mmol) was dissolved in DMF 
(4mL) and cooled it down to 0oC using ice bath. DCC (165mg, 0.80mmol) was added and 
stirred it for 1h at same temperature. In a separate reaction flask Val-Amprenavir(4) (500mg, 
0.46mmol) was dissolved in DMF,  and triethylamine (2mL) was added and stirring was 
continued for 10min at room temperature under inert atmosphere to neutralize the TFA salt 
as well as activate the primary amine group of Val-Amprenavir. This was added to reaction 
mixture, removed from ice bath and continued stirring for 48h. Reaction mixture was filtered 
and solvent was evaporated at room temperature under reduced pressure to get crude product. 
The product BocGly-Val-Amprenavir (8) was purified by silica column chromatography 
using 70% Ethyl acetate/ Hexane as eluent with 87% yield. The final product Gly-Val-
Amprenavir (9) was achieved after deprotection of the N-Boc group following the same 
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procedure as mentioned for the synthesis of Val-Amprenavir. Synthetic schemes are provided 
as Figure 8. 
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Figure 8. Synthetic scheme for Valine-APV (VA), Valine-Valine-APV (VVA) and Glycine-
Valine-APV (GVA) 
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Identification of the Prodrugs 
    Mass analysis was carried out using the same LC-MS/MS spectrometer as 
mentioned earlier under Enhanced Mass (EMS) mode. Electron-spray Ionization (ESI) was 
used as an ion method and was operated in positive and negative ion modes. In the IR spectra 
for prodrugs, characteristic peak for –OH group at 3200-3400 cm-1 was not observed.  1H 
NMR spectra were recorded on Varian Mercury 400 Plus spectrometer using tetra methyl 
silane as an IS. Chemical shifts (δ) are reported in parts per million relative to the NMR 
solvent signal.  
VA (4): Yellowish solid; LC/MS(M/z): 605.4,; 1H NMR (CDCl3) δ: 0.75, [6H, CH3; valine], 
1.01 [6H, CH3], 2.0 [1H, NH2; valine], 3.75 [2H,CH2-CH2; tetrahydrofuran],  3.99 [2H, CH2-
CH; tetrahydrofuran], 5.0,5.11 [-CH-; methane], 6.74, 6.74, 7.68, 7.68 [4H, aromatic], 7.08, 
7.12, 7.12, 7.21, 7.21 [5H, aromatic], 7.08, 7.12, 7.21, 7.68, 7.68,  6.74 [6H, aromatic], 8.0 
[1H, NH-C=O; sec. amide]. 
VVA (6): White solid; LC/MS(M/z): 704.4,; 1H NMR (CDCl3) δ: 0.7-1.0 [12H, CH3,val-val], 
1.1 [6H, CH3], 2.0 [1H, NH2; valine], 3.75 [2H,CH2-CH2; tetrahydrofuran],  3.99 [2H, CH2-
CH; tetrahydrofuran], 5.0,5.11 [-CH-; methane], 6.74, 6.74, 7.68, 7.68 [4H, aromatic], 7.08, 
7.12, 7.12, 7.21, 7.21 [5H, aromatic], 7.08, 7.12, 7.21, 7.68, 7.68,  6.74 [6H, aromatic], 8.0 
[2H, NH-C=O; sec. amide]. 
GVA (9):  Yellowish solid, LC/MS(M/z): 662.6,; 1H NMR (CDCl3) δ: 0.8-1.1 [12H, CH3], 
2.1 [1H, NH2; glycine], 3.75 [2H,CH2-CH2; tetrahydrofuran],  3.99 [2H, CH2-CH; 
tetrahydrofuran], 4.0 [1H, NH2, aromatic], 5.0,5.11 [-CH-; methane], 6.74, 6.74, 7.68, 7.68 
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[4H, aromatic], 7.08, 7.12, 7.12, 7.21, 7.21 [5H, aromatic], 7.08, 7.12, 7.21, 7.68, 7.68,  6.74 
[6H, aromatic], 8.0 [2H, NH-C=O; sec. amide]. 
 
Aqueous Solubilities 
Solubility studies were carried out in DDW. Saturation solubility values of V-APV, 
VV-APV and GV-APV were found to be, 0.61± 0.07, 0.36 ± 0.06 and 0.47 ± 0.12 mg/mL 
respectively relative to 0.04 ± 0.008 mg/mL for APV. These values are much higher relative 
to APV which is practically insoluble in water. Such increase in solubility offers an added 
benefit for a drug like APV which is almost completely insoluble in water and may offer 
some formulation-related advantages.  
Buffer Stability 
Degradation rate constants for APV prodrugs are summarized in Table 2. Stability of 
V-APV, VV-APV and GV-APV was examined within a pH range of 1.4-9.4. Apparent first 
order degradation kinetics was observed for all the prodrugs. APV prodrugs exhibited similar 
pH rate profiles within the pH range studied with VV-APV and GV-APV being more stable 
than Val-APV. No appreciable degradation of prodrugs was noticed even at pH 1.4 for 7 
days at 37oC. Increased susceptibility to hydrolysis was observed as the pH was raised 
toward the alkaline range. It is clear from these studies that prodrugs are prone to alkali 
hydrolysis.  
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 Table 2.  Half-lives (hr) and degradation rate constant (kobs) of APV prodrugs as a function 
of pH. Phthalate (pH 3.4 and 5.4), phosphate (7.4), and borate (pH 9.4) buffers (50 mM) 
were employed. Hydrochloric acid was used to prepare the pH 1.4 solution. Ionic strength 
adjusted to 0.1 M with KC1. Studies were conducted at 37oC. Values reported are mean ± SD 
(n=3) 
 ND: No degradation detected 
 
 
 
 
 
 
pH V-APV VV-APV GV-APV 
 kobs (hr-1 × 104) t1/2 (hr) kobs (hr-1 × 104) t1/2 (hr) kobs (hr-1 × 104) t1/2 (hr) 
1.4 ND ND ND ND ND ND 
3.4 31.4 ±  2.1 221 ± 2 24.2 ± 3.5 286 ± 13 24.9 ± 2.1 278 ± 26 
5.4 101.9 ± 13 68 ± 11 57.3 ± 5.6 121 ± 9 60.3 ± 4.9 115 ±12 
7.4 330 ± 46 21 ± 3 112 ± 17 62 ± 4 144 ± 14 48 ± 4 
9.4 756  ± 126 9 ± 1.4 317 ± 41 22 ± 3.3 355 ± 35 19 ± 2 
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Cytotoxicity Studies 
Cytotoxicity of the prodrugs was determined using MTT assay. Results are depicted 
in Figure 1. Medium containing no drug was used as negative control. Medium containing 
DMSO at 2% was also tested to confirm that DMSO is not cytotoxic at that concentration. 
Triton X was used as positive control. At the end of 4h, 5-50µM of prodrug concentrations 
(VA, VVA and GVA were not significantly cytotoxic but when used at concentrations of 100 
and 250µM, GVA exhibited some cytotoxicity to the cells. For transport experiments that 
were carried out for 3h, the concentrations of VVA and GVA used were 25µM which are not 
cytotoxic to the cells. 
 
 
 
 
Figure 9. Cytotoxicity of Prodrugs in MDCKII-WT cells determined by MTS assay. 
Asterisk (*) represents statistical difference compared to control at p<0.05 
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Interaction of APV, Val–Val–APV and Gly–Val–APV with P-glycoprotein 
Uptake of APV, VA, VVA and GVA by MDCKII-MDR1 cells, was studied. 
Equimolar concentrations (25 µM) are used. Approximately 2-3 fold increase in cellular 
accumulation of VA, VVA and GVA compared to APV was observed (Figure 10). This 
increase in the cellular uptake of prodrugs may be due to reduced affinity of prodrugs for 
efflux proteins. To further delineate interaction of these prodrugs with P-gp, uptake of a P-gp 
substrate [3H]digoxin (0.5 µCi/mL) was studied in presence of P-gp inhibitor GF120918, 
APV and prodrugs. GF120918 is a well-established inhibitor of P-gp. Equimolar 
concentrations (25 µM and 50 µM) of APV, VA, VVA and GVA were used. A fourfold 
increase in uptake of [3H]digoxin was observed in presence of GF120918 at 2 and 5 µM 
concentrations. A three folds increase in uptake of [3H]digoxin was observed in presence of 
APV and only two fold increase was observed in presence of VVA and GVA (Figure 11). 
The increase in uptake of [3H]digoxin in presence of GF is due to inhibiting activity of P-gp. 
However this increase in uptake was inhibited by prodrugs VA, VVA, and GVA. But 
inhibition in uptake is more compared to parent drug APV. These results demonstrate that 
prodrugs have lower affinity for P-gp compared to parent drug APV.  
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Figure 10. Uptake of 25 µM  APV, V-AAPV, VV-APV, GV-APV  in MDCKII-MDR1 cells 
(*) indicates statistical significant difference compared to Uptake in presence of APV at 
p<0.05.  
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Figure 11. Uptake of [3H] digoxin in MDCKII-MDR1 cells in presence of APV, V-APV, 
VV-APV, GV-APV at 25 µM and 50 µM concentrations. Data points expressed as mean ± 
SD.  (*) indicates statistical significant difference compared to Uptake in presence of APV at 
p<0.05. 
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Interaction with Peptide Transporters in MDCKII-MDR1 Cells   
Uptake of 3H-glycylsarcosine (GS), a model substrate for peptide transporters, in the 
presence of unlabeled glysar and prodrugs was carried out to determine if the prodrugs are 
recognized by the peptide transporters. Uptake of 3H-glysar (0.5µCi/mL), was inhibited in 
the presence of unlabeled glysar GS, at concentration 20mM. Uptake of 3H-GS was also 
significantly lower (more than 50%) in the presence of relatively low amounts of prodrugs 
(25 and 50 μM) as demonstrated in Figure 12. These studies suggest that peptide transporters 
are expressed and functional, and the prodrugs are recognized by these membrane proteins. 
 
Figure 12. Uptake of [3H] glysar (0.5 µCi/mL) by MDCKII-MDR1 cells in absence (control) 
and in presence of 20 mM unlabeled glysar, APV, val-APV, val-val-APV and gly-val-APV 
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at 25 µM and 50µM concentrations). Data is expressed as mean ±SD. * P<0.05 which 
represents statistical significant difference compared to control.  
 
 
Transport across MDCKII-MDR1  
To further test our hypothesis that prodrug modification of APV can bypass P-gp 
mediated efflux and increase absorption, transepithelial transport studies were conducted in 
MDCKII-MDR1 cell monolayers. The difference in apical to basolateral and basolateral to 
apical clearly indicates the involvement of P-gp in transport of substrates. The apical cell 
layer expresses functional efflux protein P-gp, as well as influx (peptide) transporters; which 
makes it convenient for us to compare the permeability values of both the parent drug and the 
prodrugs in the same cell line. For P-gp substrates A-B transport will be significantly lower 
than B-A. Ratio of B-A and A-B permeability, termed as efflux ratio, will be close to unity 
for drugs which are not substrates and higher than one for substrates. Permeabilities of the 
prodrugs (25μM) were compared with APV (25μM) across the apical cell layer of the 
MDCKII-MDR1. Absorptive permeability (A-B) of APV was 1.1×10-6 cm/s and secretory 
permeability was found to be 4.5 ×10-6 cm/s (Table 3). The efflux ratio of APV is 
approximately 4. This asymmetric permeability is due to the expression of P-gp on apical 
membrane. In presence of GF120918 (5 µM) efflux ratio was 1.3 (Figure 13). This clearly 
demonstrates that APV is good substrate for P-gp. A-B permeability of VVA and GVA were 
found to be 6.27 ×10-6 cm/s and 7.1×10-6 cm/s respectively. Both prodrugs also exhibited 
asymmetric permeabilities however; efflux ratio for both prodrugs was between 1.5 and 2. 
This result clearly indicates that the prodrugs have significantly lower affinity for P-gp 
compared to drug.  Bidirectional transport studies of prodrugs across MDCKII-
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MDR1 were studied in absence and presence of glysar (20mM) to delineate the interaction of 
prodrugs with peptide transporters. Results are depicted in Figure 14.  Glysar is well 
established substrate of peptide transporter. Permeability of VVA and GVA were found to be 
7.9 + 0.7x10-6 cm/sec and 9.8 + 1.2x10-6 whereas 1.6+ 0.2x10-6 for APV. In presence of 
glysar (20mM) permeability of VVA and GVA reduced to 3.2 + 0.5x10-6 cm/sec and 2.9 + 
0.6 x10-6 cm/s respectively. Peptide transporters are known to be expressed on apical 
membrane of MDCKII-MDR1 cells. The change in absorptive permeability of prodrugs is 
due to competitive binding of glysar to peptide transporter. Cellular accumulation and 
bidirectional transport results of prodrugs in presence of glysar clearly demonstrate that the 
prodrugs are substrates for peptide transporters.  
 
 
 Table 3. Apparent permeabilities 
(Papp) of APV and its prodrugs (25µM) 
across MDCKII- MDR1 cells Values 
are expressed as mean ± SD 
 
 
 
 
 
 
 
Compound  Papp (A-B) 
(×10-6 cm/s)  
Papp (B-A)  
(×10-6 cm/s)  
APV  1.1 ±0.2  4.5 ± 0.3  
APV + GF  1.9 ± 0.3  2.8 ± 0.1  
V-APV  4.39 ± 0.3  5.9 ± 0.4  
VV-APV  6.27 ± 0.2  8.2 ± 0.9  
GV-APV  7.1 ±0.5  10.8 ± 1.0  
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Figure 13. Bidirectional transepithelial transport of APV (25 µM) across MDCKII-MDR1 
cell monolayers in presence and absence of GF 120918. Data points are expressed as mean 
± S.D. (n=4). 
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Figure 14. Permeabilities of VA, VVA and GVA relative to APV across MDCKII-MDR1 
cells and in presence of 20 mM glysar. (*) represent statistical significant difference from 
control at p<0.05. (**) represent statistical significant difference from prodrug without glysar 
at p<0.01 
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Conclusions 
Di-peptide prodrugs of APV, L-valine-L-valine-Amprenavir (VVA) and L-glycine-L-
valine-Amprenavir were synthesized and evaluated for drug-transporter interactions in vitro. 
Synthesized prodrugs were identified by LC-MS/MS and NMR studies. Both prodrugs 
exhibited better inherent aqueous solubility compared to parent drug. VA, VVA and GVA 
exhibited less affinity for efflux protein P-gp compared to drug. Efflux ratios obtained from 
permeability studies clearly indicate that prodrugs have less affinity for P-gp compared to 
drug. Uptake and transport studies in presence of glysar clearly suggest that these prodrugs 
are substrates for peptide transporters, hence can evade the efflux and exhibit better 
permeability characteristics compared to drug resulting in improved bioavailability. Evasion 
of efflux may reduce the drug exposure to intestinal metabolizing enzymes and also 
minimize the chance of developing resistance on chronic APV exposure. Thus efficient 
delivery of APV will result in improved therapeutic efficacy and clinical outcomes. Results 
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obtained from this study clearly demonstrate di-peptide prodrug derivatization is a viable 
strategy to improving the oral absorption of APV.  
 
 
 
 
 
 
 
 
 
CHAPTER 4 
PROTEIN BINDING, METABOLIC AND ENZYMATIC STABILITY OF AMPRENAVIR 
PRODRUGS 
Rationale 
Amprenavir (APV) is a potent inhibitor of the human immunodeficiency virus and 
shares some pharmacokinetic properties with other protease inhibitors. The protease 
inhibitors, the mainstay of life-prolonging drug combinations used in the treatment of 
patients with acquired immunodeficiency syndrome (AIDS), are highly bound to plasma 
proteins, predominantly to alpha1- acid glycoprotein (AAG) (Boffito et al., 2003). In vitro 
studies have shown that the antiviral efficacy of the protease inhibitors was attenuated by the 
addition of human AAG to the medium. Like almost all of the commercially available HIV 
protease inhibitors, amprenavir exhibits a high degree of binding to plasma proteins (90%). 
The in vitro studies have shown that the plasma protein to which amprenavir primarily binds 
is AAG. APV is also substrate for cytochrome P450 3A4 and has inhibitory and inducing 
properties leading to a number of drug interactions. APV shares some pharmacokinetic 
properties with other protease inhibitors: it is a substrate for cytochrome P450 3A4 and has 
inhibitory and inducing properties leading to a number of drug interactions (Barry et al., 
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1999). Approximately 90% binds to plasma proteins, predominantly to AAG (Sadler et al., 
2001). The recommended dose is 1200 mg bid (or 1400 mg fosamprenavir bid), but this can 
be halved by pharmacoenhancement with low-dose (100 mg) ritonavir, a potent CYP3A 
inhibitor (Sadler and Stein, 2002). It is now recognized that virologic efficacy of protease 
inhibitors is dependent on both their pharmacokinetic and pharmacodynamic properties. 
Briefly, unbound concentrations of the antiretroviral drug have to exceed the concentration 
that inhibits viral replication in vitro (determined by IC50 or IC90), and the inhibitory quotient, 
is the ratio of plasma trough concentration to in vitro IC50 or IC90, as proposed to measure the 
in vivo potency of antimicrobial agents.(Piliero, 2002; Aarnoutse et al., 2003). Therefore, an 
increase in plasma AAG level under pathological conditions may result in treatment failure 
in such patients (due to higher binding and the resultant lower concentration of the free drug) 
unless the dosages of the drugs are adjusted appropriately.  
The majority of drugs bind reversibly to plasma proteins (e.g., serum albumin, AAG, 
lipoproteins) or other biological materials, such as erythrocytes (Kremer et al., 1988; Schmidt 
et al., 2008). In addition, there are also plasma proteins which have a high affinity towards 
certain hormones (e.g., transcortin, thyroxine-binding globulin). Of these proteins, human 
serum albumin (HSA) and AAG are frequently the main binding partners for drugs in plasma 
(Israili and Dayton, 2001; Bertucci and Domenici, 2002). While HSA is primarily 
responsible for the binding of acidic drugs, basic drugs display greater affinity for AAG 
(Piafsky, 1980; Kopecky et al., 2003). Neutral drugs can be bound to both HSA and AAG.  
However, these are general statements and are not a steadfast rule, since some drugs can bind 
to both HSA and AAG. Moreover, unlike HSA, AAG concentrations fluctuate dramatically 
in various disease conditions and inflammations (Israili and Dayton, 2001).  This may 
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severely affect therapeutic efficacy of drugs which primarily bind to AAG. Plasma 
concentration of AAG is 0.4-1.1 mg/dL and may change under various physiological and 
pathological conditions (such as during the acute-phase reaction), resulting in alteration of 
the binding of various drugs and other ligands. Changes in drug binding and, consequently, 
alteration in the levels of unbound (free) drug (Cf) can have a significant effect on both the 
pharmacokinetics and pharmacodynamics of a drug (Meijer and Van der Sluijs, 1987; 
Belpaire and Bogaert, 1989). The binding of drugs to plasma proteins is often the first 
controlling step in drug distribution. Binding is an important determinant not only of drug 
action (both therapeutic and toxic) but also of disposition (Dayton et al., 1973; Wilkinson, 
1983; Belpaire and Bogaert, 1989).  
Cytochrome P450 (CYP) is the most prevalent drug metabolizing enzymes and is 
present predominantly in the intestine and liver. CYP3A4 is the most abundant form in the 
CYP-family (Kolars et al., 1992). CYP3A group represents the major drug-metabolizing 
enzyme and accounts for approximately 30% of hepatic CYP and more than 70% of 
intestinal CYP activity. Moreover, CYP3A is estimated to metabolize between 50% and 70% 
of currently administered drugs (Watkins, 1997). CYP3A4 enzyme is present in the liver and 
enterocytes (Guengerich et al., 1986). A significant amount of CYP3A is expressed in the 
enterocytes to metabolize xenobiotics during their transit across intestinal epithelium. All 
currently available HIV-1 protease inhibitors are metabolized by CYP3A4 (Jayakanthan et 
al.). As the HIV-1 treatment employs HAART practice, the co-administration of protease 
drugs leads to CYP3A4-related drug-drug interactions occur for metabolic clearance and for 
which elevated plasma concentrations are associated with serious and/or life-threatening 
events. The simple reason for this is to one drug modulates the metabolism of other (drug–
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drug interactions) by simple competition for the same active site, and/or by binding in an 
allosteric region of the same enzyme (Tanaka, 1998). Amprenavir undergoes extensive first 
pass metabolism by CYP3A4. Ketoconazole (selective CYP3A4 inhibitor) inhibited the 
formation of major amprenavir metabolites. 3.7 µM of ritonavir completely inhibited the 
biotransformation of amprenavir by human liver microsomes (Treluyer et al., 2003). 
Metabolism of ritonavir, on the other hand, is caused by CYP3A4 and CYP2D6. It 
significantly inhibits the metabolism of CYP3A4 substrates like nifedipine and CYP2D6 
substrates like dextromethorphan, when administered in combination (Hsu et al., 1998). In 
addition to oxidative metabolism, conjugation reactions may play an important role in 
detoxification of xenobiotics from the small intestine. Specific molecules are effluxed into 
intestinal lumen after being conjugated with a glucuronide or sulfate moiety within 
enterocytes. 
Prodrugs are designed to be therapeutically inactive until in vivo activation to the 
parent drug, hence reliable in vivo activation of the prodrug is considered critical for their 
pharmacological activity (Han and Amidon, 2000). Thus controlling the mechanism of in 
vivo activation of prodrugs can be critical for prodrug delivery. Enzymatic and chemical 
processes are known to play an important role in the hydrolysis of prodrugs and it is well 
known that enzymatic processes play dominant role than chemical process (Anand et al., 
2003). It is also well known that hydrolytic enzymes are present ubiquitously in all biological 
fluids and tissues. For example, esterases are expressed throughout the body and can be 
utilized in the hydrolysis of an ester functional group. The prodrug to drug conversion can 
take place by various enzymes in different tissues, by peptidases in the intestine (Das and 
Radhakrishnan, 1976); by esterases in the skin (Roy and Manoukian, 1994); by 
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phosphomonoesterases in plasma; by β-glucuronidases at tumor tissue (Watanabe et al., 
1981). Hydrolases (esterases, peptidases, lipases, glycosidases, etc.) are enzymes well suited 
to use for drug inactivation since they are ubiquitously distributed. Insertion of ester bonds 
susceptible to enzymatic cleavage may represent one approach to make the action of a drug 
more restricted to the site of application (Graffner-Nordberg et al., 1998).  
Di-peptide drugs synthesized have an ester linkage between drug and the first amino 
acid and peptide linkage between two amino acids. Hence, two major pathways of enzymatic 
degradation are possible. One possible pathway is regeneration of amino acid prodrug from 
di-peptide prodrug by aminopeptidases followed by regeneration of parent drug from 
enzymatic hydrolysis by esterases such as carboxylesterases and cholinesterases. Another 
possible enzymatic hydrolytic pathway is regeneration of parent drug directly from di-
peptide prodrug through enzymatic hydrolysis by esterases. In order to clearly understand the 
fate of prodrug and its permeation into brain, clear understanding of enzymatic hydrolysis 
pathways is necessary.  
The objective of this study is to determine protein binding affinity of APV prodrugs 
to plasma protein AAG and determining the binding affinities. Moreover APV is metabolized 
by CYP3A4 enzyme. Metabolic stability of APV prodrugs compared to drug was evaluated. 
For prodrugs to regenerate parent drug, enzymatic hydrolysis of prodrugs is necessary and 
rate limiting step in our pro-pro-drug (PPD) approach to improve oral and brain absorption 
simultaneously. Hence enzymatic stability of prodrugs in presence and absence of peptidase 
and esterase inhibitors was performed to delineate major pathway of enzymatic hydrolysis.  
Materials and Methods 
Materials 
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APV was a generous gift from GlaxoSmithKline USA, (Philadelphia, PA). All the prodrugs 
used in the study were synthesized according to the methods noted in Chapter 3. Sprague–
Dawley rat plasma was purchased from Valley Biomedical Inc. (Winchester, VA). IGS 
Sprague–Dawley rat liver microsomes were obtained from XenoTech LLC (Lenexa, Kansas). 
Bestatin was purchased from USB Corporation (Cleveland, Ohio). Eserine and 4-
(hydroxymercuri) benzoic acid sodium salt (PCMB) were obtained from Sigma Chemical 
Co. (St. Louis, MO). Human alpha 1-acid glycoprotein (AAG) was obtained from Sigma 
Chemical Co. (St. Louis, MO).   Ketoconazole was obtained from Sigma Chemical Co. (St. 
Louis, MO). All other chemicals and solvents were purchased from Sigma Chemical Co. (St. 
Louis, MO) or Fisher Scientific Co. (Pittsburgh, PA). Male Sprague-Dawley rats were 
obtained from Charles River Laboratories (Wilmington, MA). Tissues were harvested in 
accordance to protocols approved by the IACUC at University of Missouri-Kansas City.  
Determination of in vitro Protein Binding  
The protein binding of APV and prodrugs in rat plasma were determined using ultra-
filtration technique reported previously (Barrail et al., 2006). Briefly, stock solutions (100 
µL) of APV or prodrugs in isotonic phosphate-buffered saline (IPBS), pH 7.4, containing 8 
g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, and 0.24 g/L KH2PO4, were added into 900 µL 
blank rat plasma to yield final concentrations of 10 µM. Equal volume of fresh IPBS (pH7.4) 
replaced drug solutions to be used as control to evaluate non-specific adsorption and plasma 
binding. During the 30 min-equilibration at 37C, spiked plasma samples were agitated 
gently every 10 min. Then 500 µL samples were transferred to Amicon ultra-0.5mL 
centrifugal filters (10 k NMWL, Millipore Corporation, Bedford, MA) and centrifuged at 
10,000 g, 37C, for 1 h. Around 250 µL of ultra-filtrate containing the unbound drug was 
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obtained in basolateral chamber. After centrifugation, aliquots of filtered (200 µL) and 
unfiltered (20 µL, diluted with IPBS to 200 µL) samples were taken and analyzed using LC-
MS/MS immediately to calculate protein binding of drugs in rat plasma. Unbound fraction 
(fu) was calculated by the ratio of drug in the filtered samples to the sum of filtered and 
unfiltered samples. Similarly to determine the affinity of APV and prodrugs, various 
concentrations of drugs ranging from 1-50 µM were incubated with 0.5 mg/mL of AAG 
dissolved in IPBS. Solutions were incubated for 30 minutes at 37C. These solutions were 
transferred to Amicon ultra-0.5mL centrifugal filters (10 k NMWL, Millipore Corporation, 
Bedford, MA) and centrifuged at 10,000 g, 37C, for 1 h. 250 µL of ultra-filtrate containing 
the unbound drug was obtained in basolateral chamber. After centrifugation, aliquots of 
filtered (200 µL) and unfiltered (20 µL, diluted with IPBS to 200 µL) samples were taken 
and analyzed using LC-MS/MS immediately to determine unbound drug concentration.  
Stability in Rat Liver Microsomes 
Rat liver microsomes were employed to study the prodrug affinity for CYP3A4 
relative to APV. Individual incubations (final volume 1mL) consisted of 0.2 mg/mL 
microsomal protein in 100mM phosphate buffer (pH 7.4) with final concentrations of 5mM 
magnesium chloride, 5mM glucose 6-phosphate, 1mM b-NADP1, and 1U/mL glucose 6-
phosphate dehydrogenase. The drug/prodrug (25 μM), buffer, and microsomes were mixed 
and kept at 37°C for 5min. The reaction was initiated by adding the NADPH generating 
system. Incubations were conducted at 37°C. The metabolic reaction was stopped by adding 
equal volumes of ice-cold acetonitrile: methanol (5:4) mixture. Samples were stored at −80˚C 
until further analysis.  Both time dependent and concentration dependent stability studies 
were performed.  
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For time dependent degradation studies, various test compounds (25µg/mL) were 
incubated with activated liver microsomal solution, respectively. Degradation study was 
conducted for a period of 2 h. At predetermined time points 100 µL of samples were 
withdrawn and equal volume of acetonitrile was added to terminate the degradation process. 
Samples were stored at -80° C until further analysis with LC-MS/MS. For concentration 
dependent degradation studies, various concentrations of test compounds ranging from (1-20 
μM) were incubated with activated microsomal solution for 5 min. Enzymatic degradation 
was terminated by adding equal amount of acetonitrile and samples in -80° C until further 
analysis with LC-MS/MS. To determine the effect of ketoconazole, which is well known 
substrate of CYP3A4, drugs/prodrugs were incubated for five minutes with microsomes in 
presence and absence of ketoconazole.  
Stability in Tissue Homogenate  
Male Sprague-Dawley rats were euthanized by a lethal injection of sodium 
pentobarbital through the tail vein (100 mg/kg). Intestinal segments, livers and brain were 
isolated and stored at -80°C. Tissues were homogenized in 10 mL of chilled isotonic 
phosphate buffered saline (IPBS) with a tissue homogenizer (Multipro variable speed 
homogenizer, DREMEL; Racine, WI) in an ice bath. Subsequently, the homogenates were 
centrifuged at 14,000g for 25 min at 4°C to remove cellular debris, and the supernatant was 
used for hydrolysis studies. Suitable dilutions were made to achieve a final protein 
concentration of 1.0 mg/mL. Protein content was determined according to the method of 
Bradford (Bradford, 1976) with BioRad protein estimation kit. Supernatant was equilibrated 
at 37°C for about 30 minutes prior to initiation of an experiment. Intestinal, liver and brain 
homogenate studies were initiated by adding 0.5 mL of l00µM prodrug stock solution to 4.5 
70 
 
mL of tissue homogenate. The control consisted of 4.5 mL of IPBS instead of supernatant. 
Aliquots (50µL) were withdrawn at appropriate time interval for up to 24 hr. Samples were 
immediately diluted with equal volumes of ice-cold acetonitrile:methanol (5:4) mixture to 
stop the enzymatic reaction and then stored at -80°C until further analysis. Apparent first 
order rate constants were calculated and corrected for any chemical hydrolysis observed in 
the control 
Enzymatic Hydrolysis Studies 
Enzymatic hydrolysis of APV prodrugs was determined in triplicate in rat plasma in 
the presence or absence of various hydrolytic enzyme inhibitors. Frozen Sprague–Dawley rat 
plasma was thawed quickly before experiment and diluted to 85% (v/v) with IPBS (pH 7.4) 
to maintain the pH of solution. Prior to the initiation of hydrolysis study, plasma and 
intestinal homogenate were equilibrated at 37oC for 15 min after adding enzyme inhibitors. 
The concentrations for enzyme inhibitors PCMB (p-chloromercuribenzoic acid), eserine, 
bestatin, were 1, 1, and 0.5 mM respectively, were well within the acceptable range. 
Hydrolysis was initiated in a test tube by the addition of APV or prodrug solution to 1mL 
plasma or intestinal homogenate in the presence or absence of enzyme inhibitor. Final 
prodrug concentration in the reaction mixture was 25µM. Test tubes were incubated at 37oC 
in a shaking water bath (45 rpm) and aliquots (50 µL) were withdrawn at appropriate time 
intervals for up to 24 h. Samples were immediately diluted with 50 µL chilled acetonitrile to 
quench the reaction, and centrifuged at 12,500 rpm for 15 min to precipitate protein. The 
supernatants were stored at -80oC until further analysis by LC–MS/MS. 
Sample Preparation and Analysis 
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Protein binding, enzymatic and liver microsomal stability samples were analyzed 
using a highly robust and sensitive LC-MS/MS technique. Samples were prepared using 
liquid-liquid extraction technique and verapamil (100 nM) as internal standard. Briefly, 100 
µL of verapamil and acetonitrile was added to each sample. Then, 600 µL of water saturated 
ethyl acetate was added and samples were vortexed for 2 min. This process allowed test 
compounds to partition between organic and aqueous phase. Following vortexing, samples 
were centrifuged at the speed of 10,000 rpm for 7 min for separation of two layers. 
Approximately, 500 µL of organic layer was carefully separated and evaporated under 
reduced pressure for 45 min. The residue was reconstituted in 100 µL solution of 70 % 
acetonitrile and 30% water containing 0.1% formic acid and analyzed using LC-MS/MS 
technique. Similarly, standard solution of test compounds (0.3-5 µg) were extracted and 
analyzed with LC-MS/MS.  
LC-MS/MS analysis 
Protein binding, enzymatic and microsomal stability samples were analyzed using 
LC–MS/MS technique. QTrap® LC–MS/MS mass spectrometer (Applied Biosystems/Sciex) 
equipped with Agilent 1100 series quaternary pump (Agilent G1311A), vacuum degasser 
(Agilent G1379A), and autosampler (Agilent G1367A) was used. Electrospray ionization 
(ESI) in positive mode was used for sample analysis. Test compounds were detected in 
multiple-reaction monitoring (MRM) mode. Briefly, test compounds were separated using a 
reverse phase XTerra® MS C18 column with dimensions of 4.6 x 50 mm and particle size of 
5 µm. Mobile phase (70% acetonitrile and 30% water containing 0.1% formic acid) was 
continuously pumped through the column at a constant flow rate of 0.25 mL/min. 20µL of 
samples were injected in the system and chromatographs were obtained for 5.5 min.  
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Precursor ions of test compounds were determined from spectra which are generated with the 
infusion of standard solutions to the electrospray source with the aid of an infusion pump. 
Each of these precursor ions is subjected to collision-induced dissociation to produce product 
ions. Precursor and product ion for test compounds were APV + 506.3/155.9; VVA + 
704.4/156.1; GVA + 662.4/156.0; VA + 605.4/156.0 and Verapamil (IS) + 455.3/165.1. The 
turbo ion spray setting and parameters were optimized (IS voltage: 5500 V, temperature: 
300° C, nebulizer gas: 40 psi, curtain gas: 40 psi). Nitrogen gas was used as collision gas. 
Other operational parameters included declustering potential (DP): 95 V; collision energy 
(CE): 70 V; entrance potential (EP): 8.5 V; and collision cell exit potential (CXP): 4.0 V. 
These parameters were generated by running analytes of interest in quantitative optimization 
mode. The analytical data for each test compounds generated with MRM method generated a 
significant linearity up to ng/mL range. With the help of this method, rapid and reproducible 
results were successfully obtained. Peak areas for test compounds and internal standard were 
determined using AnalystTM software.  
Data Analysis 
For protein binding studies, unbound drug concentrations vs. concentration was 
plotted. Scatchard plot, bound/free vs. bound of saturation binding data was plotted. The 
binding data was fit into ligand binding model as given below. The data was analyzed using 
Prism® (GraphPad Software, La Jolla, CA). 
𝐵 = 𝐵 𝑚𝑎𝑥 ×
𝐶𝑢 
𝐾𝑑+𝐶𝑢 
+ 𝑁𝑆 × 𝐶𝑢   …………………………………….Eq. 1.   
Where Kd is the equilibrium dissociation constant, Bmax is binding capacity, Cu is fraction 
unbound and NS is non-specific binding. In order to avoid the non-specific binding, pure 
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AAG was used instead of plasma and siliconized tubes or coated with Sigmacote® were used 
to avoid drug binding to plastic.  
For oxidative metabolism studies, Ke and t1/2 of each drug in rat liver microsomes were 
calculated by plotting the natural logarithm of drug concentrations versus time. The data of 
metabolic rates (substrate turnover per minute per milligram microsomal protein) were fit to 
Michaelis–Menten equation by nonlinear regression to determine the kinetic parameters Km 
and Vmax. Data modeling was conducted using KaleidaGraph (Synergy Software, Reading, 
Pennsylvania). In vitro intrinsic clearance (CLint) was subsequently represented by dividing 
Vmax by Km as shown in Eq. 2. 
𝑉 = 𝑉 𝑚𝑎𝑥 ×
[𝑆]
𝐾𝑚+ [𝑆] 
  ……………….. Eq. 2. 
Where V represents the total rate of uptake, Vmax is the maximum uptake rate for the carrier-
mediated process, Km (Michaelis–Menten constant) is the concentration at half-saturation, 
and [S] is the substrate concentration. For hydrolytic metabolism study in rat plasma and 
tissue homogenate, degradation rate constants (Kd) were calculated by plotting the natural 
logarithm of drug concentrations against time, and t1/2 were estimated by degradation rate 
constants. 
Results and Discussion 
Protein Binding 
APV and prodrugs (10µM) were incubated in rat plasma for 30 minutes at 37oC. From 
the samples obtained by ultrafiltration followed by centrifugation, unbound fraction of the 
drug was determined. Results are summarized in Table 4.Unbound fraction of VVA and 
GVA was found to be 1.41 ±0.16 and 1.18 ±0.08 whereas 0.68 ±0.09 for APV. Unbound 
fraction of VA is comparable to drug (0.82 ±0.1). Percentage of unbound drug was found to 
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be 7 for APV & 13 and 11 for VVA and GVA. This data clearly suggest that the di-peptide 
prodrugs have less or comparable binding to plasma proteins. However this study was 
performed using plasma where several plasma proteins are present. Other than plasma 
proteins, various enzymes are also present because of which we may not exactly translate this 
data into exclusive protein binding.  
In order to delineate the affinity of APV and prodrugs to plasma AAG, concentration 
dependent protein binding studies were performed. Physiological concentration of AAG 
varies from 0.4 to 1.1 mg/mL. Hence various concentrations of drugs were incubated with 
0.5 mg/mL AAG in IPBS pH 7.4. Free unbound fraction of drug/prodrug was measured after 
ultrafiltration followed by centrifugation. The data obtained was fit into saturation binding 
model and binding parameters Equilibrium dissociation constant (Kd) and binding capacity 
(Bmax) were calculated using Graphpad Prizm
® software. To minimize the non-specific 
binding, drug binding was determined in AAG solution and all siliconized tubes or 
Sigmacote® coated tubes were employed. The results obtained were depicted in Table 5.  
The saturation binding data and Scatchard plots were depicted in Figure 15 (for APV and V-
APV) and Figure 16 for (VV-APV and GV-APV). The X-intercept from the Scatchard plot 
gives Bmax and Y-intercept gives Bmax/Kd. As explained earlier, Kd is equilibrium dissociation 
constant, concentration at which binding site is half occupied. 1/ Kd gives the affinity and 
Bmax is the binding capacity. APV exhibited Kd value of 5.99 ± 1.02 µM whereas VA, VVA 
and GVA has Kd of 7.43 ± 1.55, 9.88 ± 1.63 and 11.44 ± 1.9 µM respectively. These results 
clearly demonstrate that VVA and GVA exhibited reduced affinity in binding to AAG 
compared to drug. VA has reduced or equal affinity for binding to AAG. However, Bmax 
values for drug and prodrugs were comparable. Bmax value of APV was found to be 17.35 
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nmoles/mg and VA, VVA and GVA has Bmax values 19.03, 19.44 and 24.57 nmoles/mg. 
Decrease in affinity and comparable binding capacity clearly suggest that the prodrugs are 
easily displaceable from protein compared to drug. Moreover, reduced AAG binding affinity 
may result in increased free drug concentration available for therapeutic efficacy. Other than 
plasma, AAG is known to be present in various organs in the body including vascular 
endothelial cells. Hence it is 
advantageous to have more 
unbound drug in brain vascular 
endothelial cells.  
 
 
 
 
Table 4. Unbound fraction (fu) of APV and prodrugs (10 µM) in rat plasma. Data represented 
are mean ± SE (n = 4). *P < 0.05 statistical difference between APV and prodrug values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Unbound fraction 
 (ƒu) 
Percentage of 
 unbound drug 
APV 0.68 ±0.09 7 
V-APV 0.82 ±0.1* 9 
VV-APV 1.41 ±0.16* 13 
GV-APV 1.18 ±0.08* 12 
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Figure 15. in vitro Saturation protein binding kinetics of APV (top) and V-APV (bottom) 
obtained by incubating 1-50µM of APV and V-APV with 0.5 mg/mL of plasma protein 
alpha 1- acid glycoprotein(AAG). Values are expressed in mean ± SD. 
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Table 5. in vitro protein binding kinetic parameters of APV,  V-APV, VV-APV and GV-
APV obtained by incubating 1-50µM of APV and V-APV with 0.5 mg/mL of plasma protein 
alpha 1- acid glycoprotein(AAG). (*) indicates statistical significant difference compared to 
APV at p<0.05. Values are expressed in mean ± SD. 
  
Kd (µM) 
 
Bmax (nmoles/mg) 
APV 5.99 ± 1.02 17.35 ± 1.06 
V-APV 7.43 ± 1.55 19.03 ± 1.53 
VV-APV 9.88 ± 1.63* 19.44 ± 1.35 
GV-APV 11.44 ± 1.9* 24.57 ± 2.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  in vitro Saturation protein binding kinetics of VV-APV (top) and GV-APV 
(bottom) obtained by incubating 1-50µM of VV-APV and GV-APV with 0.5 mg/mL of 
plasma protein alpha 1- acid glycoprotein(AAG). Values are expressed in mean ± SD. 
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Metabolic stability Studies 
 
APV undergoes extensive first pass metabolism and primarily metabolized by 
CYP3A4. Hence we tried to determine the metabolic stability of prodrugs and affinity of 
prodrugs toward CYP3A4 in comparison to drug. Metabolic stability of APV and prodrugs in 
rat liver microsomes (0.2 mg/mL) was determined. Degradation rate constant and half-life 
were determined. The first order degradation rate profiles (percentage of drug/prodrug 
remaining vs. time) were shown in Figure 17. Degradation rate constants and half-lives were 
given in Table 6. Degradation rate constant of amino acid prodrug V-APV was found to be 
0.009 min-1 whereas 0.013 min-1 for APV. Di-peptide prodrugs VV-APV and GV-APV 
exhibited 1.76 and 1.65 times slower degradation compared to drug with degradation rates 
0.0068 and 0.0071 min-1 respectively. These results clearly suggest that the di-peptide 
prodrugs have slightly reduced affinity for metabolic enzymes in rat liver microsomes and 
exhibited 1.7 times longer half-lives.  
In order to further confirm these results, concentration dependent metabolism was 
performed. APV and prodrugs with concentrations ranging from 1-20µM were incubated 
with 0.2 mg/mL rat liver microsomes for 10 minutes. By fitting the data in Michaelis-Menten 
kinetic model, we determined Km and Vmax values. The results were depicted in Table 7. 
prodrugs exhibited slightly low affinity with Km values 9.1 ± 2.4 µM for VA,  9.3 ± 3.0 µM 
for VVA and 9.9 ± 3.7 µM for GVA whereas Km for APV is 6.2 ± 2.0 µM. These results 
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clearly demonstrate that the prodrugs have less affinity for metabolizing enzymes. Intrinsic 
clearance of drug/prodrugs was calculated from ratio of Vmax and Km. Among all the 
prodrugs VV-APV has less intrinsic clearance (0.22 mL/min/mg protein) compared to APV 
(0.36 mL/min/mg protein). To further compare the metabolic stability of prodrugs vs. drug, 
stability of drug/prodrugs was determined after incubating in 0.1 mg/mL rat liver 
microsomes for 10 minutes in presence and absence of ketoconazole (10µM). Ketoconazole 
is a well-known inhibitor of CYP3A4. In presence ketoconazole, amount of APV remaining 
is approximates 40% more compared to control which is APV without ketoconazole. Results 
from this study are represented in Figure 18. For all the prodrugs these is no significant 
difference was observed between control and in presence of ketoconazole. This study was 
performed with very low concentration of microsomes (0.1mg/mL) in order to compare the 
metabolic stability and affinity of prodrugs for CYP enzymes. From all these studies it is 
clear that prodrugs have better metabolic stability than APV and slightly lower affinity for 
CYP enzymes. Thus these prodrugs may bypass first pass effect to a significant amount 
compared to drug.  
 
Table 6. Degradation rate constants and half-lives of APV and prodrugs in rat liver 
microsomes. Study was conducted in rat liver microsomes (0.2 mg/mL) at 37oC.  Values are 
expressed as mean ± SD (n=4) 
 kobs × 102   
(min-1)  
t1/2   
(min)  
Fold 
difference in 
t1/2  
APV  1.21 ± 0.09  57 ± 8   
V-APV  0.95 ± 0.01  73 ± 5  1.26 
VV-APV  0.68 ± 0.01  101 ±  12  1.76  
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GV-APV  0.71 ± 0.01  95 ± 7  1.65  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Enzymatic degradation profiles of APV and prodrugs (10µM) in rat liver 
microsomes (0.2mg/ml) at pH 7.4 for two hours. 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Amount of drug/prodrug remaining after 5 min incubation with rat 
liver microsomes (0.1 mg/ml), in presence and absence of Ketoconazole. Data 
points are expressed as mean ±SD, n=4. (*) represents significant difference 
from control 
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Table 7. Kinetic parameters Km, Vmax and in vitro intrinsic clearance (CLint) of APV and 
prodrugs in 0.2 mg protein/mL rat liver microsomes (mean ± SD, n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compounds Vmax (nmoles/min/mg protein) Km  (µM) CLint (mL/min/mg protein) 
APV 2.3 ± 0.4 6.2 ± 2.0 0.38  ± 0.03 
V-APV 3.2 ± 0.5 9.1 ± 2.4 0.31  ± 0.02 
VV-APV 2.0 ± 0.3 9.3 ± 3.0 0.22  ± 0.01 
GV-APV 3.0 ± 1.0 9.9 ± 3.7 0.29  ± 0.02 
84 
 
 
 
 
 
 
 
 
 
 
 
Stability in Tissue Homogenates 
 The half-lives for prodrugs of APV in intestinal, liver and brain homogenate have 
been summarized in Table 8. The di-peptide ester prodrugs are first converted to amino acid 
prodrug and then further degraded to the active parent drug, APV. The major pathways of 
enzymatic hydrolysis appeared to be cleavage of the peptide and ester bond. There was no 
significant difference in the half-lives of Val- Val-APV and Gly-Val-APV in liver and 
intestinal homogenates. Significant difference between V-APV and di-peptide prodrugs was 
noted.  
 
 
 
Table 8. Half-lives (hr) of APV prodrugs in intestinal, brain and liver homogenate (1 
mg/mL). Studies were conducted at 37°C. Values reported are mean ± SD (n=3). 
compound Intestinal 
homogenate 
(t ½ mins) 
Brain 
Homogenate 
(t ½  mins) 
Liver 
homogenate 
(t ½  mins) 
V-APV 220 ± 15 120 ± 13 25 ± 6 
VV-APV 290 ± 40 173 ± 12 32 ±2 
GV-APV 230 ± 10 140 ± 13 22 ± 5 
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Enzymatic stability studies 
Enzymatic stability of prodrugs was measured in rat plasma (85%) diluted with IPBS 
to maintain the pH (7.4). In plasma all the prodrugs, VA, VVA, and GVA exhibited better 
stability.  First order degradation rate constants and half-lives were determined by plotting 
log concentration vs. time and are shown in Table 9. The di-peptide prodrugs VVA and GVA 
have half-life of 64 ± 9 and 28 ± 2 minutes respectively whereas half-life of VA was found to 
be 50 ± 13 minutes. Among all the prodrugs VVA exhibited better stability.  
The di-peptide prodrugs VVA and GVA have ester linkage between valine and APV 
and a peptide linkage between both amino acids. In order to determine the hydrolytic 
pathway, degradation profile of prodrugs in plasma in presence and absence of enzyme 
inhibitors was performed. The di-peptide prodrug may undergo enzymatic hydrolysis at two 
possible positions. The possible enzymatic degradation pathways are depicted in figure 19. 
One possibility is enzymatic bioreversion of PPD to PD by plasma amino peptidases 
followed by subsequent conversion of PD to D. Another possibility is simultaneous activity 
of both aminopeptidases and carboxylesterases which result in formation of PD and D 
simultaneously from PPD. Another possibility is direct activity of esterases on PPD 
generating D directly without forming the intermediate PD. For the proposed hypothesis, to 
improve brain absorption, mean residence time of PD is necessary and rate limiting step. In 
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Oder to determine which the most predominant pathway is, we determined the stability of 
prodrugs in plasma in presence of bestatin (0.5mM), eserine (1mM) and PCMB (1mM). 
Bestatin is a competitive and specific inhibitor of aminopeptidases. Eserine is cholinesterase 
irreversible inhibitor whereas PCMB is carboxyl esterase inhibitor and sulfhydryl group 
modifier.  First order degradation rate constants and half-lives are given in Table 9.  
 
 
 
 
 
pro       pro         APV 
Peptide 
bond 
Ester  
bond 
P-P-Drug 
P-Drug 
Drug 
P-P-Drug 
P-Drug 
Drug P-P-Drug 
P-Drug 
Drug 
(a) 
(d) (c) 
(b) 
Figure 19. (a) Position of ester and peptide bonds in di-peptide pro-pro-drug (PPD). 
(b) Possible enzymatic degradation pathways involved in bioreversion of PPD. (c) 
Pathway inhibited by peptidase enzyme inhibitors. (d) Pathways inhibited by 
esterase inhibitors. 
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ND: No significant degradation; ---: not determined  
 
 
 
 
 
Table 9. Degradation rate constant and half-life of APV and prodrugs in presence and 
absence of enzyme inhibitors: Bestatin (aminopeptidase inhibitor), Eserine (cholinesterase 
inhibitor), PCMB (carboxylesterase inhibitor). Study was performed at 37o for 24 hours. 
Values are expressed as mean ±S.D. n=3. 
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Figure 20. Concentration vs. time degradation of profile of GV-APV in 85% rat plasma in 
absence (control) (top) and presence of bestatin (0.5mM) (bottom). Data points are 
expressed as mean ± SD, n=3 
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In presence of bestatin rate of degradation of GVA was reduced from 2.46 × 10-2min-1 
(control) to 0.124 × 10-2 min-1. This clearly suggests that when bestatin inhibited peptidase 
enzyme activity half-life of GVA increased from 28 minutes to 561 minutes. It is clear that 
GVA did not undergo enzymatic hydrolysis by esterases to a significant amount. Rate of 
degradation of GVA in presence of Eserine and PCMB (both esterase inhibitors) was found 
to be 2.0 × 10-2min-1 and 2.6 × 10-2min-1 respectively, which is comparable with control 
without any inhibitors. These results suggest that peptidase inhibitors increased degradation 
rate tremendously whereas esterase inhibitors have little or no effect on degradation rate. 
Similar trend was observed with VVA. In presence of bestatin no significant degradation of 
VVA was observed. However in presence of eserine and PCMB no significant difference in 
rate of degradation was observed. From these results it is clear that bioreversion of GVA and 
VVA to VA is the predominant pathway compared to GVA and VVA regenerating drug 
directly by esterase activity. Enzymatic stability of amino acid prodrug VA was also tested. 
Surprisingly VA exhibited better enzymatic stability with degradation rate of 1.38 × 10-2min-
1 which is inhibited approximately ten times by eserine. In presence PCMB no significant 
degradation of VA was observed.   
Even though these results give a clear indication that GVA and VVA undergo 
sequential hydrolysis, we determined different rate constants for GVA. Degradation profile 
Figure 21. Concentration vs. time degradation of profile of GV-APV in 85% 
rat plasma in presence of eserine (1mM) (top) and presence of PCMB (1 mM) 
(bottom). Data points are expressed as mean ± SD, n=3 
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of GVA in plasma control and in presence of bestatin was depicted in Figure 20.  Similarly 
degradation profile of GVA in presence of eserine and PCMB was depicted in Figure 21. In 
control GVA degraded completely in about 150 minutes and regeneration of VA and APV 
can be clearly seen. However in presence of bestatin rate of degradation of GVA, formation 
of VA and APV was significantly slowed down. In presence of eserine and PCMB, no 
significant difference in rate of degradation of GVA was observed. However rate of 
formation of APV was significantly slowed which is due to inhibition of esterase activity. 
Different rates k11, k21 were estimated by using Phoenix WinNonlin® software and fitting 
amount of amino acid prodrug, VA, generated vs. time in one compartmental model with 
first order elimination. Results are given in Table 10. GV-APV in plasma control exhibited 
degradation rate k11 as 1.8 × 10-2min-1 and k21 0.4 × 10-2min-1. In presence of bestatin rate of 
formation of VA, k11 was reduced by 20 times to 0.09 × 10-2min-1, which in turn increase 
degradation half-life of VA regenerated from GV-APV. However in presence of PCMB, no 
significant difference in k11 compared to control was observed but k21 was reduced to 0.05 
× 10-2min-1 and is comparable with k21 in presence of bestatin. Overall, in presence of 
peptidase inhibitor, rate of formation of VA was inhibited which in turn affected rate of 
degradation of VA. However in presence of PCMB, rate of formation of VA is same as rate 
of degradation of GV-APV control but degradation of VA to APV was significantly 
inhibited. This negligible k21 in presence of enzyme inhibitors clearly suggest that undergoes 
sequential hydrolysis of di-peptide pro-pro-drug is more prominent compared to ester 
hydrolysis of pro-pro-drug to drug.  
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Table 10. Degradation rate constants of GV-APV in plasma in presence and absence of 
bestatin (0.5mM) and PCMB (1mM). Values are expressed as mean ± SD. n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 k11 
 (× 10
2 min-1) 
t1/2  
(min) 
k21 
 (× 10
2 min-1) 
t1/2 
 (min) 
GV-APV 1.8 ± 0.4 42 ± 13 0.4 ± 0.03 188 ± 61 
GV- APV + Bestatin(0.5mM) 0.09 ± 0.02 720 ± 122 0.04 ± 0.005 1460 ± 298 
GV-APV + PCMB (1 mM) 1.4 ± 0.2 48 ± 8 0.05 ± 0.008 1589 ± 339 
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Conclusions 
APV binds to plasma proteins and 90% of the drug binds to AAG. Protein binding of 
drugs significantly alters both pharmacokinetic and pharmacodynamics properties of drugs. 
Protein binding studies performed in rat plasma using ultrafiltration technique revealed that 
7% of APV is unbound to plasma proteins. Prodrugs VVA and GVA has 13 and 12 % drug 
was unbound to plasma proteins. Since only unbound fraction of drug can exert 
pharmacological action, in terms of unbound fraction, approximately 60 % increase is 
observed. To further determine the affinity of APV and prodrugs with AAG, concentration 
dependent binding to AAG was performed. The Kd values clearly indicate that prodrugs have 
less affinity for AAG compared to APV. However the maximum binding Bmax is comparable 
for drug and prodrugs. The saturation binding data clearly suggest that prodrugs are binding 
to single binding site at AAG. With low affinity and comparable maximum binding, prodrugs 
can be easily displaceable compared to drug which may result in high protein unbound 
fractions compared to APV are possible with prodrugs. Metabolic stability studies clearly 
demonstrate that prodrugs exhibited better stability than drug itself. Intrinsic clearance of 
94 
 
drugs in vitro was significantly reduced for prodrugs. It is clear from the metabolism studies 
that prodrugs have better metabolic stability and less affinity for CYP enzymes. Results from 
enzymatic stability studies clearly suggest that di-peptide prodrugs undergo sequential 
hydrolysis. Di-peptide PPDs can be cleaved by esterases and peptidases. Degradation rate 
constants and half-lives of prodrugs in plasma in presence and absence of enzyme inhibitors 
clearly demonstrates that peptide hydrolysis following ester hydrolysis is predominant 
pathway compared to direct ester hydrolysis generating drug directly from PPD. This may 
result in longer residence time of amino acid PD in systemic circulation following oral 
administration. It is clear that esterase activity in rat plasma is higher than human plasma. 
Slower ester hydrolysis of prodrugs may result in much longer residence time of amino acid 
prodrug in humans. Surprisingly V-APV exhibited good stability compared to other amino 
acid prodrugs synthesized in our laboratory. From the data obtained in this study and 
previous work from our laboratory suggests that valine- ester prodrugs has better stability 
due to bulky β-alkyl substitution may be responsible for good enzymatic stability of valine-
prodrug. Overall, from these studies VA, VVA, and GVA exhibited less affinity for plasma 
protein and CYP enzymes. Moreover VVA and GVA undergo sequential hydrolysis (from 
PPD to PD to D).  
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CHAPTER 5 
ORAL PHARMACOKINETICS OF AMPRENAVIR AND PRODRUGS 
Rationale 
Protease inhibitors (PIs) constitute an important class in highly active antiretroviral 
therapy for the treatment of acquired immune deficiency syndrome (AIDS). However oral 
bioavailability of PIs is limited due to low aqueous solubility, interaction with membrane 
efflux proteins, extensive systemic metabolism. Hence very high doses of PIs are 
administered. For example Amprenavir (Agenerase®) dose is 1200 mg (twenty four 50 mg 
capsules) twice daily in combination with other antiviral agents. Transporter-targeted 
prodrug modification could be a good approach to improve its oral bioavailability of PIs. 
Structural modification of drug molecules compromises the interaction between parent drug 
and transporters/enzymes. Peptide transporters, mainly expressed in intestinal epithelial cell 
membranes, are attractive targets for prodrug design due to their broad substrate specificity 
and high capacity. Therefore “peptidomimetic” prodrugs, designed by conjugating parent 
drug to small peptides, can be recognized easily by the peptide transporter-mediated influx 
system and ferried across the epithelial membranes at absorption site (Ganapathy et al., 
1995).  In the previous chapters 3 and 4, it was clearly demonstrated that prodrugs of 
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amprenavir (APV), V-APV, VV-APV and GV-APV exhibited better intrinsic aqueous 
solubility and low affinity for efflux proteins such as P-gp compared to APV. We clearly 
demonstrated that with the di-peptide and amino acid prodrug approach, P-gp mediated 
efflux can be circumvented as well as prodrugs can be translocated across cell membrane via 
nutrient influx transporters. Moreover the prodrugs exhibited better hydrolytic and metabolic 
stability. These prodrugs also possess less affinity for plasma AAG compared to drug. The 
aim of this study was to investigate whether prodrug modification can result in enhanced oral 
absorption of poorly absorbed protease inhibitor APV. In vitro permeability studies were 
carried out using Caco2 as a model. To further substantiate our results, in vivo oral 
pharmacokinetics of di-peptide ester prodrugs, V-APV, VV-APV, and GV-APV were 
investigated. Pharmacokinetic parameters were evaluated for prodrugs relative to the parent 
drug, APV followed by single dose oral administration in Sprague-Dawley rats. 
Materials and Methods 
Materials 
APV was a generous gift from GlaxoSmithKline USA, (Philadelphia, PA). All the 
prodrugs used in the study were synthesized according to the methods noted in Chapter 3. 
Colon carcinoma cell line, Caco-2 (passages 20-30) obtained from ATCC (Manassas, VA, 
USA). High-performance liquid chromatographic grade DMSO and methanol were obtained 
from Fisher Scientific Co. (Pittsburgh, PA, USA). These solvents were used neat for 
preparing stock solutions of all drugs and inhibitors. Trypsin-EDTA solution, Dulbecco’s 
modified Eagle’s medium (DMEM), Ham’s F-10 medium and Minimum Essential Medium 
(MEM) were obtained from Invitrogen (Carlsbad, CA, USA). Fetal Bovine Serum (FBS) was 
obtained from Atlanta biologicals (Lawrenceville, GA, USA). Transwell® and uptake plates 
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were procured from Corning Costar Corp (Cambridge, MA, USA). All other chemicals were 
of analytical reagent grade and were obtained from Fisher Scientific or Sigma Chemicals. 
Jugular vein cannulated rats male Sprague-Dawley rats were obtained from Charles River 
Laboratories (Wilmington, MA). All the experiments were conducted in accordance to 
protocols approved by the IACUC at University of Missouri-Kansas City.  
 
Methods 
Cell Culture 
Caco-2 cells were cultured in T-75 flasks with DMEM (with high glucose and 
glutamine concentrations) supplemented with 10% FBS, 1% nonessential amino acids, 
penicillin 100µg/mL and streptomycin 100U/mL. The medium was changed every alternate 
day; cells were harvested and passaged via trypsinization at 80 to 90% confluence (about 4 
days of growth). Cells were also grown on collagen coated Transwell® inserts (12-mm) with 
transparent polyester membranes. Transwell® inserts were coated with type 1 rat tail collagen 
(100µg/cm2), equilibrated with medium, and seeded at a 25,000 cells/cm2 density. Following 
seeding, medium was changed every alternate day, and transport or uptake studies were 
performed after incubation of 17-21 days.  
Transport Studies 
APV transport was evaluated with monolayers of each cell line. All transport studies 
were performed with Dulbecco’s modified phosphate-buffered saline (DPBS) containing 
glucose (1g/L) and HEPES (20mM) at pH 7.4. Drug solutions were prepared immediately 
prior to initiating a transport study. APV and prodrugs (VA, VVA and GVA) were dissolved 
in DMSO (not exceeding 2% v/v as the final concentration) to prepare a stock solution and 
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then diluted with DPBS to the specified final concentrations. Volumes of test solutions added 
were 0.5 and 1.5mL, for apical (A) and basolateral (B) chambers respectively. Prior to 
initiating an experiment, cultured monolayers were rinsed and equilibrated for 30min with 
DPBS. Drug solution was added either in the donor or receiving chamber for A to B transport 
study. Samples (100µL) were withdrawn from the receiving chamber at predetermined time 
points (15, 30, 60, 90, 120, 150 and 180) and were replaced with equal volume of DPBS to 
maintain sink conditions. Dilutions were taken into account for the calculations. Samples 
were stored at −80˚C until further analysis. All the experiments were performed at 37˚C in 
triplicate. Similar transport studies were performed for prodrugs in presence of 10 and 20 
mM of glysar. 
Oral Absorption Studies 
Oral absorption studies of APV and its prodrugs were carried out by administering 
49.5 μmol/kg to male Sprague-Dawley rats. Equimolar dose corresponds to 25 mg/kg of 
APV. Rats weighing 200-300 g, were fasted overnight 8-12 hrs but were allowed water ad 
libitum prior to an experiment. Drug solutions were prepared by dissolving in 40% v/v of 
PEG400 and 60% v/v water. Drugs/prodrugs were administered by oral gavage (maximum of 
0.8 mL) to jugular vein cannulated rats. Blood samples (200 μL) were collected from the 
jugular vein cannula at predetermined time intervals over 8 hours. The withdrawn blood will 
be replaced with 200 μL of 100IU/mL of sterile heparin saline solution to constantly 
maintain the fluid volume and avoid clogs in the cannula. Plasma was separated immediately 
by centrifugation and samples were stored at –80°C until further analysis. 
Sample Preparation and Analysis 
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Transport and rat plasma samples were analyzed using a highly robust and sensitive 
LC-MS/MS technique. Samples were prepared using liquid-liquid extraction technique and 
verapamil (100 nM) as internal standard. Briefly, 100 µL of verapamil and acetonitrile was 
added to each sample. Then, 600 µL of water saturated ethyl acetate was added and samples 
were vortexed for 2 min. This process allowed test compounds to partition between organic 
and aqueous phase. Following vortexing, samples were centrifuged at the speed of 10,000 
rpm for 7 min for separation of two layers. Approximately, 500 µL of organic layer was 
carefully separated and evaporated under reduced pressure for 45 min. The residue was 
reconstituted in 100 µL solution of 70 % acetonitrile and 30% water containing 0.1% formic 
acid and analyzed using LC-MS/MS technique. Similarly, standard solution of test 
compounds (0.3-5 µg/mL) were extracted and analyzed with LC-MS/MS.  
LC-MS/MS Analysis 
Both in vitro transport and in vivo plasma samples were analyzed using LC–MS/MS 
technique. QTrap® LC–MS/MS mass spectrometer (Applied Biosystems/Sciex) equipped 
with Agilent 1100 series quaternary pump (Agilent G1311A), vacuum degasser (Agilent 
G1379A), and autosampler (Agilent G1367A) was used. Electrospray ionization (ESI) in 
positive mode was used for sample analysis. Test compounds were detected in multiple-
reaction monitoring (MRM) mode. Briefly, test compounds were separated using a reverse 
phase XTerra® MS C18column with dimensions of 4.6 x 50 mm and particle size of 5 um. 
Mobile phase (70% acetonitrile and 30% water containing 0.1% formic acid) was 
continuously pumped through the column at a constant flow rate of 0.25 mL/min. 20uL of 
samples were injected in the system and chromatographs were obtained for 5.5 min. 
Precursor ions of test compounds were determined from spectra which are generated with the 
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infusion of standard solutions to the electrospray source with the aid of an infusion pump. 
Each of these precursor ions is subjected to collision-induced dissociation to produce product 
ions. Precursor and product ion for test compounds were APV + 506.3/155.9; VVA + 
704.4/156.1; GVA + 662.4/156.0; VA + 605.4/156.0 and Verapamil (IS) + 455.3/165.1. The 
turbo ion spray setting and parameters were optimized (IS voltage: 5500 V, temperature: 
300° C, nebulizer gas: 40 psi, curtain gas: 40 psi). Nitrogen gas was used as collision gas. 
Other operational parameters included declustering potential (DP): 95 V; collision energy 
(CE): 70 V; entrance potential (EP): 8.5 V; and collision cell exit potential (CXP): 4.0 V. 
These parameters were generated by running analytes of interest in quantitative optimization 
mode. The analytical data for each test compounds generated with MRM method generated a 
significant linearity up to nanogram range. With the help of this method, rapid and 
reproducible results were successfully obtained. Peak areas for test compounds and internal 
standard were determined using Analyst TM software.  
Data Analysis 
Cumulative amounts of prodrugs (VVA or GVA), the intermediate VA and the parent 
drug APV, generated during transport across the cell monolayers were plotted as a function 
of time to determine permeability coefficients. Linear regression of the amounts transported 
as a function of time yielded the rate of transport across the cell monolayer (dM/dt). Rate 
divided by the cross-sectional area available for transport (A) generated the steady state flux 
as shown in Eq. 1. 
Flux=(dM/dt)/ A    Eq. 1 
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In all the transport studies, slopes obtained from the linear portion of the curve were used to 
calculate permeability values. Permeability was calculated by normalizing the steady state 
flux to the donor concentration (Cd) of the drug or prodrug as shown in Eq. 2.  
Permeability=Flux/Cd    Eq. 2 
 
All relevant pharmacokinetic parameters were calculated using non-compartmental analyses 
of plasma-time curves after oral administration of APV, and the amino acid and di-peptide 
prodrugs of APV using a pharmacokinetic software package Phoenix® WinNonlin®, version 
6.3 (Pharsight, Mountain View, CA). Maximum plasma concentrations (Cmax) and area under 
the plasma concentration time curves (AUC0-inf) were obtained from the plasma-
concentration time profiles using non-compartmental analysis. The slopes of the terminal 
phase of plasma profiles were estimated by log-linear regression and the terminal rate 
constant (λz) was derived from the slope. The terminal plasma half-lives were calculated 
from the equation: t1/2= 0.693 / λz. Mean residence time (MRT) was calculated as area under 
the first moment curve (AUMC)/AUC, respectively. The total concentration parameters were 
calculated by adding the concentrations of the administered prodrug (PPD) and the 
regenerated PD and APV 
Statistical Analysis 
All experiments were conducted at least in triplicate and results are expressed as 
mean ± S.E.M/S.D. Statistical comparison of mean values were performed with one way 
analysis of variance (ANOVA) or Student t test (Graph Pad INSTAT, version 3.1). *P <0.05 
was considered to be statistically significant.  
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Results and Discussion 
Permeability of the Prodrugs across Caco-2 Cells 
Caco-2 cell line is an established in vitro model for intestinal absorption. Hence 
permeabilities of prodrugs in comparison with APV was determined across apical cell 
monolayers. Permeability of prodrugs was compared with APV. Equimolar concentration of 
(25 μM) APV, V-APV, VV-APV and GV-APV have been used for transport study. 
Permeability values are presented in Table 11.  All prodrugs exhibited 2-3 time high apparent 
permeability compared to drug. Significantly higher permeabilities of V-APV, VV-APV and 
GV-APV (9.5 x10-6, 6.97 x10-6 , 7.28 x10-6  cm/s respectively) as compared to 2.3 x10-6  cm/s  
for APV. Approximately 3.5 fold improvement in flux of prodrugs was observed. To further 
determine role of peptide transporter in the flux of prodrugs, permeabilities of prodrugs in 
presence of glysar (GS, 10 and 20mM) was determined (Figure 22.).  Permeabilities of V-
APV, VV-APV and GV-APV were found to be 4.8x10-6 , 3.2x10-6 and 4.2 x10-6   cm/sec in 
the presence of 10mM GS and 3.6x10-6 , 2.9 x10-6  and 3.9x10-6 cm/sec in the presence of 
20mM GS respectively. This result confirmed our previous conclusion from uptake studies 
that absorptive flux of prodrugs is significantly inhibited in the presence of GS. This study 
also indicated that prodrugs are good substrates for the peptide transporters expressed on the 
intestinal barrier and may be translocated efficiently resulting in higher oral bioavailability.  
 
 
 
 
 
Table 11. A→BTransport of APV and its prodrugs across Caco2 cell monolayers. 
Permeability values are expressed as mean ±SD, n=4 
Drug  Permeability (10 -6 
cm/s) 
APV 2.32 ± 1.07  
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V-APV 9.5 ± 2.8 
VV-APV 6.97 ± 1.6 
GV-APV 7.28 ± 2.1 
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Oral Absorption Studies 
Figure 22. Permeability of APV, V-APV, VV-APV and GV-APV across Caco-2 
cell monolayers. Asterisk (*) represents significant difference from control (APV) 
(p <0.05). Two asterisks (**) represent significant difference from control (when 
GS is absent) (p <0.05) 
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Plasma concentrations of APV following single dose oral administration were 
determined and plotted against time. Plasma concentration vs. time profile for APV is 
provided as Figure 23 and pharmacokinetic parameters are given in table 2. Area under curve 
for APV was 248 ± 68 min*nmoles/mL. The maximum plasma concentration observed was 
1.07 ± 0.2 nmoles/mL at time 55 ± 9 minutes post dosing. Elimination rate constant 
calculated from elimination phase was 0.017 ± 0.002 with half-life of 43 ± 5 min. Oral 
absorption of prodrugs with V-APV, VV-APV and GV-APV were also carried out to 
investigate absorption following oral dosing in Sprague-Dawley rats.  All possible 
breakdown moieties of prodrugs, such as VV-APV, V-APV, and APV for VVA, were 
monitored. Plasma concentration vs. time profiles were plotted and pharmacokinetic 
parameters were calculated for all possible breakdown products. Drug plasma concentrations 
were determined in terms of nmoles/mL and pharmacokinetic parameters of prodrugs and 
APV were compared. High plasma levels in terms of APV were observed with V-APV, VV-
APV and GV-APV. Plasma concentration vs. time profiles APV in comparison with V-APV, 
VV-APV, and GV-APV are provided in Figures 23, 24, 25 and 26 respectively. 
Pharmacokinetic parameters for drug and prodrugs are listed in Table 12. Area under plasma 
concentration time curves expressed as min*nmoles/mL for V-APV (1067 ± 323), VV-APV 
(1580 ± 261) and GV-APV (1529 ± 455) are significantly higher than APV (248 ± 68). High 
systemic concentrations of prodrugs might be due to circumvention of P-gp mediated efflux, 
minimized presystemic metabolism and translocation via peptide transporter expressed on 
intestinal epithelium. All the prodrugs exhibited higher Cmax expressed as nmoles/mL 
compared to APV (1.07 ± 0.2 for APV, 8.08 ± 1.74 for V-APV, 7.06 ± 0.3 for VV-APV, 
9.44 ± 1.8 for GV-APV). Elimination half-lives of prodrugs are 2-3 times longer than APV. 
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Pharmacokinetic parameters for all possible breakdown moieties for VV-APV and GV-APV 
are summarized in Tables 13 and 14 respectively. 
 
 
 
 
 
 
Figure 23. Plasma concentration vs time profile of APV in male Sprague 
Dawley rats following single dose (49.5 µmoles/kg) oral administration. 
Values are expressed as mean ± SD. n=3 
 
107 
 
 
 
 
 
 
 
Table 12. Pharmacokinetic Parameters of APV, V-APV, VV-APV and GV-APV after single 
dose (49.5µmoles/kg) oral administration in rats. Values expressed as mean ± SEM 
Parameter 
 
APV 
 
V-APV 
 
VV-APV 
 
GV-APV 
 
 
AUC∞ (min.nmol/mL) 
 
 
248 ± 68 
 
1067 ± 323 1580 ± 261 1529 ± 455 
Cmax (nmol/mL) 
 
1.07 ± 0.2 8.08 ± 1.74 7.06 ± 0.3 9.44 ± 1.8 
Tmax (min) 
 
55 ± 9 50 ± 8 60 ± 12 45 ± 10 
λz (min-1) 
 
0.017 ± 0.002 0.011 ± 0.002 0.005 ± 0.001 0.007  ± 0.002 
t1/2 (min) 
 
43 ± 5 94  ± 22 142 ± 30 99  ± 17 
MRTinf (min) 
 
67 ± 15 107 ± 18 208 ± 40 162  ± 29 
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Figure 24. Plasma concentration vs time profile of APV and V-APV in male Sprague Dawley 
rats following single dose (49.5µmoles/kg) oral administration. Values are expressed as mean 
± SD. n=3 
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Figure 26. . Plasma concentration vs time profile of APV and GV-APV in male Sprague 
Dawley rats following single dose (49.5 µmoles/kg) oral administration. Values are 
expressed as mean ± SD. n=3 
 
Figure 25. . Plasma concentration vs time profile of APV and VV-APV in male Sprague 
Dawley rats following single dose (49.5µmoles/kg) oral administration. Values are 
expressed as mean ± SD. n=3 
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 Plasma concentrations vs. time profile of all breakdown moieties were depicted in Figures 
27 and 28. When VV-APV was administered, area under plasma concentration vs. time curve 
expressed as min*nmoles/mL for VV-APV alone (474 ± 90), V-APV (868 ± 170) and APV 
(542 ± 125) are significantly higher than APV (248 ± 68). AUC of regenerated APV from 
VV-APV is two fold higher than APV itself. Among all the fragments observed AUC of V-
APV is higher. Moreover elimination of V-APV regenerated is slower than VV-APV alone 
and regenerated APV. Interestingly mean residence time expressed as min for V-APV moiety 
(213 ± 12) is longer than VV-APV alone (146 ± 29) and regenerated APV (151± 29). This 
observation clearly suggests that V-APV is more stable in plasma and elimination is slower. 
Similarly for GV-APV, AUC expressed as min*nmoles/mL for GV-APV alone (287 ± 43), 
regenerated V-APV (767 ± 101) and regenerated APV (412 ± 106) was higher than APV 
(248 ± 68). Like VV-APV, among all possible moieties from GV-APV, regenerated V-APV 
has higher AUC compared to GV-APV alone and regenerated APV. Mean residence time 
expressed as min of V-APV (193 ± 32) is much longer than GV-APV alone and regenerated 
APV. However GV-APV moiety has faster elimination rate with half-life of 29± 6 minutes, 
unlike VV-APV which exhibited elimination half-life of 106 ± 19 min. Presence of V-APV 
for longer duration is may be due to lower esterase activity due to stearic hindrance offered 
by bulk secondary β-alkyl group. These results clearly suggest that V-APV is the major 
fragment observed in plasma following VV-APV and GV-APV administration. Moreover in 
both cases the area under plasma concentration time curve (min*nmoles/mL) for regenerated 
APV from VV-APV (542 + 125) and GV-APV (412 + 106) is higher than APV (248 ± 68). 
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Figure 27. Plasma concentration vs time profile of VV-APV alone, APV and V-APV 
regenerated from VV-APV in male Sprague Dawley rats following single dose (49.5 
µmoles/kg) oral administration. Values are expressed as mean ± SD. n=3 
Figure 28. Plasma concentration vs time profile of GV-APV alone, APV and V-APV 
regenerated from GV-APV in male Sprague Dawley rats following single dose (49.5 
µmoles/kg) oral administration. Values are expressed as mean ± SD. n=3 
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Table 13. Pharmacokinetic Parameters for VV-APV alone, V-APV, APV regenerated from 
VV-APV in comparison with APV after single dose (49.5 µmoles/kg) oral administration in 
rats. Values expressed as mean ± SEM 
Parameters Val-Val-APV 
(alone) 
Regenerated 
Val-APV 
Regenerated 
APV 
APV 
 
AUC
∞
 (min.nmol/mL) 474 + 90 868 + 170 542 + 125 
 
248 ± 68 
 
Cmax (nmol/mL) 3.3 + 0.6 2.9 + 1.0 1.91 + 0.75 1.07 ± 0.2 
λz  (min
-1
) 0.008 + 0.001 0.0045 + 0.0005 0.006 + 0.001 0.017 ± 0.002 
t1/2 (min) 106 + 19 159 + 34 114 + 27 43 ± 5 
MRT
∞ 
(min) 146 + 29 213 + 12 151 + 29 67 ± 15 
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Table 14. Pharmacokinetic Parameters for GV-APV alone, V-APV, APV regenerated from 
GV-APV in comparison with APV after single dose (49.5 µmoles/kg) oral administration in 
rats. Values expressed as mean ± SEM 
(--) Not determined 
 
 
 
 
Parameters Gly-Val-APV 
(Alone) 
Regenerated 
Val-APV 
Regenerated 
APV 
APV 
 
AUC∞ (min.nmol/mL) 287 + 43 767 + 101 412 + 106 
 
248 ± 68 
 
Cmax (nmol/mL) 4.3 + 1.2 5.8 + 1.3 0.64 + 0.2 1.07 ± 0.2 
λz  (min
-1
) 0.02 + 0.003 0.006 + 0.001 -- 0.017 ± 0.002 
t1/2 (min) 29 + 6 132 + 34 -- 43 ± 5 
MRT∞ (min) 66 + 19 193 + 32 -- 67 ± 33 
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Conclusions 
 The permeability studies clearly demonstrated that prodrugs possess better 
permeability characteristics compared to APV. Reduced permeability of prodrugs in presence 
of GS clearly suggest that prodrugs are interacting with peptide transporters. Single dose oral 
absorption studies in Sprague-Dawley rats demonstrate that AUC0-∞ for APV prodrugs V-
APV, VV-APV and GV-APV is much higher than parent drug APV  indicating that the total 
amount of APV absorbed in the case of prodrugs is more than APV itself. VV-APV and GV-
APV exhibited longer MRT∞ and slower elimination compared with APV indicating that 
prodrugs possess better enzymatic and metabolic stability. Moreover AUC0-∞ for regenerated 
APV from prodrugs is two to three fold higher than APV itself. As discussed in earlier 
chapters, prodrugs have low affinity for efflux proteins and are substrates for peptide 
transporters which lead to high concentrations of drugs. Increased systemic drug levels and 
longer residence times, bypassing the efflux proteins may lead to better absorption into brain 
which serve as sanctuary site for HIV.  
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CHAPTER 6 
ABSORPTION OF AMPRENAVIR PRODRUGS ACROSS BLOOD BRAIN 
INTERFACES 
Rationale 
Protease inhibitors (PIs) are an important class of anti-HIV drugs. Their continuous 
use in the highly active anti-retroviral therapy (HAART) led to lowering deaths due to HIV 
infections. Despite of excellent anti-HIV efficacies of PIs, severely low and variable oral 
bioavailabilities have been reported when administered in humans. Brain availability of most 
of the PIs is unknown. Blood brain barrier (BBB) presents a significant challenge to the 
delivery of therapeutic agents to the brain. Tight junctions prevent free diffusion of small 
polar molecules across this barrier. However, entry of large lipid soluble molecules is also 
limited across BBB by the presence of several ABC (ATP binding cassette) efflux 
transporters i.e., P-glycoprotein (P-gp) and multi-drug resistance associated proteins (MRPs) 
which efficiently prevent entry of drug molecules into the central nervous system (CNS). 
Extensive metabolism by CYP3A4, efflux by membrane efflux transporters present on the 
absorptive membrane of the intestine and the blood-brain barrier (BBB) and extensive 
plasma protein binding are believed to contribute to such low and variable absorption of PIs. 
Low brain concentrations of PIs lead to development of safe haven for HIV in the brain 
tissues.  
In the previous chapters amprenavir prodrugs have been evaluated for their 
interaction with efflux protein P-glycoprotein and influx peptide transporters. All the 
prodrugs exhibited better absorption than parent drug APV. As per our hypothesis, peptide 
transporters are targeted at intestinal epithelium and amino acid transporters at blood brain 
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barrier (BBB). Peptide transporters are not expressed on BBB and the di-peptide prodrugs are 
good substrates of peptide transporter. In the oral absorption studies it is clear that di-peptide 
pro-pro-drug (PPD) undergoes enzymatic hydrolysis and bioreverse to amino acid prodrug 
and some amount to drug. We anticipate that the amino acid prodrug (PD) can evade the 
efflux by P-gp at BBB and translocates across BBB via amino acid transport system. We 
name this transporters targeted approach as pro-pro-drug approach as explained in Chapter 2.  
We hypothesized that systemically generated amino acid prodrug of APV will evade the 
efflux and permeate into the brain utilizing the amino acid transporters on the BBB. This pro-
prodrug strategy will not only result in enhanced oral absorption of poorly absorbed APV but 
also in higher brain concentrations of APV. In order to test our hypothesis, permeability 
characteristics of prodrugs of APV were investigated utilizing an in vitro BBB model. 
Further in vivo brain concentrations of drugs were determined in Sprague-Dawley rats 
following intravenous injection. Brain microdialysis technique was employed to study brain 
pharmacokinetics. To confirm our pro-prodrug hypothesis in possibly enhancing both 
systemic and brain concentrations of APV, it was imperative to corroborate our in vitro 
permeability results with in vivo pharmacokinetics (PK) as seen in rats. Therefore, we 
conducted brain absorption studies for pro-pro-drug (VV-APV and GV-APV) and amino 
acid prodrug (V-APV) respectively. Brain PK parameters were evaluated for GV-APV and 
V-APV following intravenous administration in cannulated rats.  
Materials and Methods 
Materials 
APV was a generous gift from GlaxoSmithKline USA, (Philadelphia, PA). All the 
prodrugs used in the study were synthesized according to the methods noted in Chapter 3. 
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High-performance liquid chromatographic grade DMSO and methanol were obtained from 
Fisher Scientific Co. (Pittsburgh, PA, USA). These solvents were used neat for preparing 
stock solutions of all drugs and inhibitors. Rat brain endothelial cells (RBE4), an immortal 
rat brain endothelial cell line, was generously provided by INSERM, France and rat 
astroctyes were purchased from ATCC (Manassas, VA, USA). Trypsin-EDTA solution, 
Dulbecco’s modified Eagle’s medium (DMEM), Ham’s F-10 medium and Minimum 
Essential Medium (MEM) were obtained from Invitrogen (Carlsbad, CA, USA) and fetal 
bovine serum (FBS) was obtained from Atlanta Biologicals (Lawrenceville, GA, USA). 
Culture flasks (75 and 25 cm2), Transwell® and 12-well plates (3.8 cm2 growth area/well) 
were obtained from Costar (Bedford, MA, USA). All other chemicals were of analytical 
reagent grade and were obtained from Fisher Scientific or Sigma Chemicals. Jugular vein-
cannulated and carotid artery-cannulated male Sprague-Dawley rats were obtained from 
Charles River Laboratories (Wilmington, MA). CMA 12 Elite 14/02 PAES probes and guide 
cannulae were obtained from CMA/Microdialysis AB (Stockholm, Sweden). All the 
experiments were conducted in accordance to protocols approved by the IACUC at 
University of Missouri-Kansas City.  
RBE4 and Astroytes Cell Culture 
 The media used to grow these cells and other cell culture conditions were similar to 
those described for MDCK cells. Cellular accumulation studies were performed on RBE4 
cell monolayers using the same protocol followed as described in Chapter 3. Transport of 
drug and prodrug was studied in RBE4 and astrocytes co-culture (Figure 29). RBE4 cells at a 
density of 250,000 cells per well grown on collagen coated A side of Transwell® inserts 
placed in uptake plates plated with astroctytes at a density of 250,000 cells per well (RBE4 & 
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AST). Transport experiments were performed and apparent permeability was measured for 
APV and prodrugs. 
 
 
 
Uptake Studies 
Cellular uptake studies in RBE4 were performed according to procedures described in 
previously published protocol from our laboratory (Patel et al. 2012). Briefly, cells were 
plated at the density of 3 x 106 cells in 12 well culture plates. Medium was aspirated and cell 
monolayer was washed with Dulbecco’s Phosphate Buffered Saline (DPBS) buffer (130 mM 
NaCl, 0.03 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM MgSO4, 
and 5 mM glucose, pH 7.4) for 10 min, three times at 37⁰ C. Uptake studies were initiated by 
incubating cells with radioactive substrates in DPBS at 37⁰ C for 15 min. Following 
incubation, radioactive solution was quickly removed and plates were washed with ice-cold 
stop solution (210 mM KCl, 2 mM HEPES, pH of 7.4) to terminate the uptake process.  One 
mL of lysis buffer (0.1% Triton-X solution in 0.3% NaOH) was added to each well for cell 
lysis. Approximately, 500 µL solutions were added from each well to scintillation vials 
RBE4 (luminal side) 
Astrocytes (abluminal side) 
Figure 29. Graphical representation of Rat brain endothelial cells (RBE4) 
and rat astrocytes co-culture model. 
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containing 3 mL of scintillation cocktail. Radioactivity associated with cells was analyzed 
with a scintillation counter (Beckman Instruments Inc., Model LS-6500; Fullerton, CA). 
Uptake rate was normalized to protein count using human serum albumin, quantified with 
BioRad protein estimation kit (BioRad protein; Hercules, CA). 
Transport Studies across RBE4 and Astrocyte Co-culture 
Transport studies were carried out according to previously published protocols (Luo et al., 
2006). Briefly, cells were cultivated in 12-well Transwell® plates as mentioned in the 
previous section. Before initiation of transport study, cell monolayers were washed with 
DBPS (pH7.4) for 15 min at 37° C (three washes). For determining A-B permeability, 0.5 
mL test solution (25 µM) was added in the apical chamber of 12-well Transwell® plates. 
Similarly, 1.5 mL test solution (25 µM) was added in the basolateral chamber to determine 
B-A permeability. Transport study was performed for 3 h at 37° C. At predetermined time 
points (5, 15, 30, 45, 60, 120 and 180 min), 100 µL sample was withdrawn from the 
receiving chamber and replaced with fresh DPBS to maintain sink conditions. Samples were 
stored at − 80° C until further analysis with LC/MS/MS technique. To study the effect of P-
gp inhibitors on transepithelial permeability of test compounds, cells were treated with 
inhibitors such as GF 120918 prior to the initiation of the experiment. Transport study of test 
compounds in presence of inhibitors was also determined for 3 h at 37° C.  
In vitro Probe Calibration 
Microdialysis probe recovery was determined in artificial CSF and a known 
concentration of APV and prodrugs (1-5µM). The probe was perfused at a constant flow rate 
of 2μL/min and samples were collected every 40 min for a period of 2h. The recovery factor 
(RF) for APV and prodrugs was calculated as a percentage according to the equation, RF = 
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Cout/Cin, where, Cout is the concentration of the drug in the dialysate flowing out of the probe 
and Cin is the known concentration of the dialysate in which the probe is dipped. Actual brain 
concentrations were then derived by dividing the dialysate concentrations by the recovery 
factor. Probe recovery efficiency for APV is 20% whereas for V-APV and GV-APV was 12-
15%.  
Brain Microdialysis Studies 
For in vivo brain microdialysis studies, V-APV was administered via intravenous 
route through jugular vein cannula. Equimolar doses of APV and prodrugs (19.8 µmoles/kg) 
which is equivalent to 10mg/kg of APV. Doses were prepared by dissolving drug/prodrug in 
PEG400 40%v/v and water 50%v/v. The rats were anesthetized before implanting 
microdialysis probe in the brain by an intra-peritoneal (IP) injection of ketamine 
hydrochloride (90mg/kg) and xylazine (10mg/kg). Thereafter ketamine (30mg/kg) was 
administered intramuscularly (IM) every 45min for maintenance of anesthesia. Animals were 
then placed on the Kopf® stereotaxic instrument. The head was fixed on this instrument at 
three places: two bony ear canals and the upper jaw. The skin over the head was shaved and 
cleaned with alcohol swabs. Using a clean, sharp sterile scalpel blade, a midline scalp 
incision was made to expose the skull. After the skin was incised, the periosteum was 
cleaned to expose the skull by a pair of tweezers. Surface of the skull was cleaned with 
cotton swabs. Bregma and lamda sites were exposed and marked. A guide cannula was fixed 
in the stereotaxic instrument and placed just above the bregma. Coordinates of the X, Y and 
Z axis on the instrument were noted and set as zero points for reference. Using the 
stereotaxic instruments guide cannula was moved 2.6mm medio-lateral and 0.9mm anterior 
relative to bregma (Roiko et al.; Zhang et al.). A hole was drilled in this area with a 2mm 
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trephine drill. The guide cannula (CMA12) was then lowered 3.9 mm ventral to the bregma 
and sealed in the place with the help of dental cement. Paxinos brain atlas was used to 
determine the brain coordinates. CMA12 microdialysis probe (2mm membrane) was inserted 
into the brain through the guide cannulae. The probe was perfused with an artificial 
cerebrospinal fluid (CSF) (140 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 1.2 mM 
Na2HPO4, 0.3 mM NaH2PO4, 3 mM glucose, 2% w/v bovine serum albumin pH 7.2) (Roiko 
et al.; Zhang et al.). The perfusion fluid was pumped at a flow rate of 2µL/min for 1h to 
attain equilibration. At this time, APV, V-APV and GV-APV were administered via jugular 
vein. Dialysate was collected every 40min to study the brain concentrations of APV and 
prodrugs. Samples were stored at -80°C until further analysis. Animals were kept under 
anesthesia for the entire duration of the experiment and euthanized under deep anesthesia by 
an over dose of sodium pentobarbital injection USP at the end of an experiment.  
LC-MS/MS Sample Preparation 
Transport, in vivo plasma and brain samples were analyzed using sensitive LC-
MS/MS technique. Samples were prepared using liquid-liquid extraction technique and 
verapamil (100 nM) as internal standard. Briefly, 100 µL of verapamil and acetonitrile was 
added to each sample. Then, 600 µL of water saturated ethyl acetate was added and samples 
were vortexed for 2 min. This process allowed test compounds to partition between organic 
and aqueous phase. Following vortexing, samples were centrifuged at the speed of 10,000 
rpm for 7 min for separation of two layers. Approximately, 500 µL of organic layer was 
carefully separated and evaporated under reduced pressure for 45 min. The residue was 
reconstituted in 100 µL solution of 70 % acetonitrile and 30% water containing 0.1% formic 
acid and analyzed using LC-MS/MS technique. Similarly, standard solution of test 
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compounds (0.3-5 µg) were extracted and analyzed with LC-MS/MS. Samples were analyzed 
as described in Chapter 5.  
Data Analysis 
Cumulative amounts of prodrugs (VVA or GVA), the intermediate VA and the parent 
drug APV, generated during transport across the RBE4 and Astrocyte co-culture model were 
plotted as a function of time to determine permeability coefficients. Flux and permeability 
values were determined as described in Chapter 3 and Chapter 5.  
All relevant pharmacokinetic parameters were calculated using non-compartmental 
analyses of plasma-time and brain concentration vs. time curves after IV administration of 
APV, and the amino acid and di-peptide prodrugs of APV using a pharmacokinetic software 
package Phoenix® WinNonlin®, version 6.3 (Pharsight, Mountain View, CA). Maximum 
plasma concentrations (Cmax) and area under the plasma concentration time curves (AUC0-inf) 
were obtained from the plasma-concentration time profiles using non-compartmental 
analysis. The slopes of the terminal phase of plasma profiles were estimated by log-linear 
regression and the terminal rate constant (λz) was derived from the slope. The terminal 
plasma half-lives were calculated from the equation: t1/2= 0.693 / λz. Mean residence time 
(MRT) was calculated as area under the first moment curve (AUMC)/AUC. The total 
concentration parameters were calculated by adding the concentrations of the administered 
prodrug (PPD) and the regenerated PD and APV 
Statistical Analysis 
All experiments were conducted at least in triplicate and results are expressed as 
mean ± S.E.M/S.D. Statistical comparison of mean values were performed with one way 
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analysis of variance (ANOVA) or Student t test (Graph Pad INSTAT, version 3.1). *P <0.05 
was considered to be statistically significant.  
Results and Discussion 
Transport Studies across RBE4  
Various publications about BBB and valid in vitro models led us to various possible 
co-cultures with different components of the BBB, such as brain endothelial cells, astrocytes, 
perictyes, and glial cells. Good permeabilities were found with co-cultures of brain 
endothelial cells and astrocytes (Ayres, 1977; Gumbleton and Audus, 2001; Deli et al., 2005; 
Nicolazzo et al., 2006). Hence in our laboratory co-culture of RBE4 and astrocytes was 
developed. Agarwal et al., studied all possible models which can be developed with RBE4 
and astrocytes and compared the permeabilities of drugs with MDCK cells. Among all the 
models developed with RBE4 and astrocytes treated with 25μg/mL of rifampicin exhibited 
better barrier properties. Rifampicin is a well know inducer of efflux protein expression. 
Transport of lopnavir was studied in our laboratory across a co-culture, containing RBE4-Rif 
cells (RBE4 cells treated with rifampicin) and astrocytes generated an efflux ratio of 2.3 
indicating significant efflux transporter activities in RBE4 cells after treatment with 
rifampicin. Hence we adapted this model study in vitro permeability characteristics of APV 
prodrugs. The concentration of APV and all the prodrugs utilized for the transport studies 
was 25μM. Figure 30, shows the A-B permeabilities obtained for all the prodrugs across 
RBE4-Rif cells.  A-B (absorptive) permeability of APV, APV in presence of GF, V-APV, 
VV-APV and GV-APV were determined. Approximately three fold increase in apprent 
permeability of APV in presence of P-gp inhibitor was observed. Similarly V-APV exhibited 
three fold increase in the permeability whereas VV-APV and GV-APV exhibited two fold 
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increase in permeability. Among all the prodrugs tested, V-APV exhibited better flux across 
the cell monolayer. It is evident from the P-gp interaction studies that all prodrugs exhibited 
low affinity for P-gp. Hence all the prodrugs tested can evade the P-gp mediated efflux. 
Moreover all prodrugs are good substrates of peptide transporters in cluding V-APV. It is 
clear from the literature that valine is the only amino acid with good affinity for peptide 
transporters (Terada and Inui, 2004; Bhardwaj et al., 2005). However, unfortunately peptide 
transporter is not expressed on BBB. The enhanced permeability of V-APV triggers a 
question whether any other transport system in responsible in translocation of V-APV. We 
wanted to further investigate the amino acid transport system involved in translocation of V-
APV. 
 
Figure 30. Permeability across RBE4-rif Astrocytes co-culture for APV and prodrugs of 
APV. Equimolar concentration of all the drugs was used (25 µM). Study was performed at 
pH 7.4. Values are expressed as mean ± S.D. n=4). (*) is considered as statistically 
significant from control. 
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Characterization of Valine Transport across RBE4 
After observing the permeability across BBB model, we investigated for transporters 
involved in translocation of valine. Cellular accumulation studies were performed using 
valine and substrates of amino acid transport systems. In the process of characterization of 
valine transport, uptake of [3H]-tyrosine in presence of phenylalanine (100µM) and valine 
(100µM) was studied. Tyrosine and phenylalanine are good substrates of system L amino 
acid transporter (Pardridge, 1998). Results obrained are shown as Figure 31. Approximately 
80% of [3H]-tyrosine uptake was inhibited in presence of phenylalanine. Both tyrosine and 
phenylalanine are well known substrates for large amino acid transport system 1(LAT1). 
Similar inhibition in uptake of [3H]-tyrosine was observed in presence of valine. This result 
clearly demonstrates that valine is interacting with LAT1 on RBE4 cells. We further 
characterized the active transport process using [3H]-valine, unlabled valne, tyrosine and 
phenyl alanine.  
Figure 31. Uptake of [3H] tyrosine in presence of Phenylalanine and valine in RBE4 
cell monolayers. Values reported are mean±S.D. (n = 4). (**) is considered as 
statistically significant from control at p<0.01.  
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Time and pH dependant uptake of [3H]-valine was determined. For time dependent 
uptake studies, [3H]-tyrosine uptake is carried out over various time points (5, 15, 30 and 45 
min). The effect of pH on [3H]-tyrosine uptake is studied by adjusting buffer pH to 4, 5, 6, 
7.4 and 8. The uptake study is carried out as described earlier at different pHs. [3H]-valine 
uptake is found to be linear up to 45 min (Figure 32). Incubation time of 15 min is selected 
for further uptake studies unless or otherwise specified. The involvement of inward proton 
gradient for [3H]-valine uptake is examined by adjusting buffer pH to 4, 5, 6 and 7.4. The 
uptake remains unaltered within a pH range of 4–7.4 indicating that the process is pH 
independent (Figure 33).  
 
 
 
 
 
 
 
 
Figure 32. Time dependent uptake of [3H]-valine in RBE4. Values are expressed 
as mean ± SD., n=4 
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The role of sodium ions on [3H]-valine uptake is delineated by substituting sodium chloride 
(NaCl) and sodium phosphate dibasic (Na2HPO4) in DPBS with equimolar quantities of 
choline chloride and potassium phosphate dibasic (KH2PO4), respectively. The absence of 
sodium ions in incubation buffer does not significantly influence [3H]-tyrosine uptake 
(Figure 34). This result clearly suggests that the uptake process is sodium independent. 
Figure 33. pH dependent uptake of [3H]-valine in RBE4. Values are 
expressed as mean ± SD., n=4 
Figure 34. Uptake of [3H]-valine in RBE4 in absence (control) and presence of valine 
and buffer and sodium free buffer. Values are expressed as mean ± SD., n=4 
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For studying saturation kinetics, [3H]-valine uptake was performed as a function of substrate 
(valine, tyrosine and phenylalanine) concentration over the range 0.01–100 µM. Figure 35 
clearly shows the involvement of a saturable carrier mediated process. The data obtained is 
fitted to classical Michaelis-Menten inetic model and kinetic parameters, Km and Vmax were 
determined. The results are summmarised in Table 15. 
 
Table 15. Km and Vmax values obtained by fitting data obtained from Uptake of [3H] valine in 
presence of various concentrations of valine, tyrosine and phenylalanine into classic 
Michaelis-Menten equation. Values expressed as mean±SD. n=4. 
 Km(µM)  Vmax  
(nmoles/mg/min)  
Valine  41.3  ±  7.8 148 ± 12 
Tyrosine  36.3 ± 4.6  176 ± 18  
Phenylalanine  41.9 ± 13.16  159 ± 13  
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Figure 35. Uptake of [3H] valine in presence of various concentrations of valine, tyrosine 
and phenylalanine (1-100µM). Km and Vmax are calculated by fitting data into classic 
Michaelis-Menten equation. Each data point is expressed as mean±SD. n=4. 
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The Km values for valine, tyrosine and phenylalanine are comparable which indicates 
affinity of valine for LAT1 is comparable with that of tyrosine and phenylalanine. Extent of 
binding is also similar to that of tyrosine and phenylalanine. These results clearly 
demonstrate that valine is translocated by LAT1 across RBE4. In order to investigate the 
interaction of V-APV with LAT1, we performed cellular accumulation studies of [3H]-valine 
in presence of various concentrations of V-APV and unlabeled valine (100µM) was used as 
positive control. The results obtained from this study are depicted as Figure 36. At all the 
concentrations tested (25, 50 and 100 µM) uptake of [3H]-valine is significantly inhibited by 
30-50%. The results clearly indicate V-APV is a substrate for LAT1 and translocated across 
BBB via system L transporter. Affinity of V-APV for LAT1 could be the reason for high 
permeability of V-APV compared with VV-APV and GV-APV.  
 
 
 
Figure 36. Uptake of [3H]-valine in presence unlabled valine (100 µM) and V-APV 
(25, 50 and 100 µM) in RBE4 cells. Data points are expressed as mean ± SD. n=4. 
(*) indicated statistical significant difference from control at p<0.05 
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Brain Absorption Studies in vivo 
Brain microdialysis studies were carried out with APV, V-APV and GV-APV in male 
Sprague-Dawley rats. In vitro transport studies clearly demonstrated that prodrugs have 
better permeability characteristics compared to APV in BBB co-culture model. Further in 
vivo evaluation of these prodrugs was conducted by intravenous administration of equimolar 
doses of drug/prodrug (19.8 µmoles/kg). Both plasma and brain samples were collected and 
analyzed for drug/prodrug concentrations. CMA12 Elite PAES microdialysis probes were 
implanted in rat brain and artificial CSF buffer was perfused continuously throughout the 
experiment and samples were collected. Brain microdialysis probe and experimental setup 
was shown in Figure 37.  
 
 
 
 
 
 
Figure 37. Brain microdialysis experimental set up. (Left) Sprague-Dawley rat mounted 
on stereotaxic instrument and skull was exposed with clear visibility of bregma and 
lambda. (Right) CMA 12 elite PAES probe with 2mm semipermeable membrane. 
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From plasma and brain concentrations, pharmacokinetic parameters were estimated. 
Figure 38, shows the concentration (nmoles/mL) vs. time profile in plasma and brain for 
APV. All the pharmacokinetic parameters are summarized in Table 16. AUC0-last in plasma 
expressed as min*nmoles/mL in plasma and brain was found to be 678 ± 148 and 66 ± 13 
respectively for APV. AUC0-last observed from brain concentrations was almost ten times less 
than that of plasma concentrations. Elimination of APV from brain is slower with half life of 
69 ± 22 min compared to elimination from blood with half life of 38 ± 15 min. The mean 
residence time calculated from ratio of area under moments curve and area under curve was 
found to be 42 ± 9 and 81 ± 17 min in plasma and brain respectively.  
 
 
 
 
 
Figure 38. Comparative plasma and brain concentration vs time profile for APV 
following intravenous administration (19.8 µmoles/kg) in Sprague Dawley rats. 
Values are expressed as mean ± SE. n=3. 
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Figure 39. Comparative brain concentration vs time profile for APV and V-APV 
(cumulative) following intravenous administration (19.8 µmoles/kg) in Sprague 
Dawley rats. Values are expressed as mean ± SE. n=3. 
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Figure 40. Comparative brain concentration vs time profile for APV and GV-APV 
(cumulative) following intravenous administration (19.8 µmoles/kg) in Sprague Dawley 
rats. Values are expressed as mean ± SE. n=3. 
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Table 16. Comparative pharmacokinetic parameters of APV, V-APV and GV-APV estimated 
from plasma and brain concentrations following intravenous administration (19.8 µmoles/kg) 
in Sprague Dawley rats. Values are expressed as mean±SD, n=3. 
 
 APV V-APV GV-APV 
 Plasma Brain Plasma Brain Plasma Brain 
AUC0-last 
(min*nmoles/ml) 
678 ± 138 66 ± 13 1131 ± 
400 
312 ± 26 1335 ± 
316 
363 ± 
112 
Cmax (nmoles/ml) 6.8 ± 0.8 0.55 ± 0.17 7.4 ± 0.53 1.29 ± 
0.32 
11.5 ± 2.1 2.18 
λz (x102min-1) 2.1± 0.4 1.2 ± 0.2 0.77 ± 0.1 0.6 ± 0.2 0.79 ± 0.2 0.6 ± 0.2 
t1/2 (min) 38 ± 15 69 ± 22 80 ± 21 115 ± 28 93 ± 19 121 ± 33 
MRTlast (min) 42 ± 9 81 ± 17 132 ± 32 175 ± 43 256 ± 52 184 ± 19 
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Prodrugs V-APV and GV-APV exhibited better brain absorption compared to APV. 
However when GV-APV was administered, we were able to determine only concentrations 
of amino acid intermediate V-APV and parent APV. The cumulative AUC0-last obtained from 
brain concentrations vs. time profile expressed as min*nmoles/mL for V-APV was found to 
be 312 ± 26 and 363 ± 112 for GV-APV. These AUCs were 4-5 folds higher than that of 
parent drug, APV. The brain concentration vs. time profiles for V-APVtotal (V-APV and 
regenerated APV) and GV-APVtotal (regenerated V-APV and regenerated APV) in 
comparison with APV are depicted in Figures 39 and 40. Both prodrugs exhibited 
comparable AUC0-last values. Even though Cmax values for V-APVtotal in brain (1.29 ± 0.32 
nmoles/mL) and GV-APVtotal (2.18 ± 0.4 nmoles/mL), are 2-3 fold higher than APV (0.55 
±0.17nmoles/mL), a 4-5 fivefold difference in AUC0-last was observed. This difference is due 
to slower elimination of both regenerated V-APV and APV, and regeneration of APV slowly 
from V-APV. Moreover mean residence times of prodrugs (175 ± 43 for V-APV and 184± 
19 for GV-APV) are longer than for APV (81 ± 17minutes). Brains vs. plasma ratios were 
calculated. Extent of brain absorption, calculated from 100× (AUCbrain/AUCplasma) was found 
to be 9.7 for APV, 27.5 for V-APVtotal, and 26.1 for GV-APV. Typically extent of brain 
absorption is calculated from ratios of steady state AUCs in brain and plasma. However for 
the comparison purposes we calculated the extent of brain absorption following single IV 
administration. Approximately three fold difference in extent of brain absorption was 
observed between APV and prodrugs.  
 In order to further conclude that prodrugs have better pharmacokinetic 
properties and result in improved therapeutic efficacy, we determined regenerated APV 
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concentrations from V-APV and GV-APV in brain and pharmacokinetic parameters were 
determined.  
 
 
 
 
 
 
 
 
 
 
Figure 41. Comparative brain concentration vs. time profile for APV and APV regenerated 
from V-APV following intravenous administration (19.8 µmoles/kg) in Sprague Dawley 
rats. Values are expressed as mean ± SE. n=3 
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Figure 42. Comparative brain concentration vs. time profile for APV and APV 
regenerated from GV-APV following intravenous administration (19.8 µmoles/kg) in 
Sprague Dawley rats. Values are expressed as mean ± SE. n=3. 
 
139 
 
 
 
 
 
Table 17. Comparative pharmacokinetic parameters of APV, APV regenerated from V-APV 
and GV-APV estimated from brain concentrations following intravenous administration 
(19.8 µmoles/kg) in Sprague Dawley rats. Values are expressed as mean±SD, n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APV 
APV regenerated 
from  V-APV 
APV regenerated 
from  GV-APV 
AUC0-last (min*nmoles/mL) 66 ± 13 182 ± 56 261.5 ± 64 
Cmax (nmoles/mL) 0.55 ± 0.17 0.67 ± 0.06 0.73 ± 0.04 
λz (x102min-1) 1.2 ± 0.2 0.7  ± 0.2 0.6 ± 0.1 
t1/2 (min) 69 ± 22 106 ± 19 127 ± 29 
MRTlast (min) 81 ± 17 152 ± 41 141 ± 22 
140 
 
Comparative brain concentration (nmoles/mL) vs. time profile for APV and 
regenerated APV from V-APV is shown in Figure 6.13. Similarly comparative brain 
concentration vs. time profile for APV and regenerated APV from GV-APV is shown in 
Figure 6.14. AUC0-last expressed as min*nmoles/mL for regenerated APV from V-APV (182 
± 56) and GV-APV (261.5 ±64) are two and three fold higher than that of APV (66 ± 13). 
High and steady concentrations of APV from V-APV and GV-APV were observed in brain. 
Elimination rate of regenerated APV was approximately 1.5 times slower than that of APV. 
Mean residence times of regenerated APV (152 ± 41min for V-APV and 141 ±22 min for 
GV-APV) are longer than that of APV (69 ±22). Moreover another important observation 
was 50-60% of V-APV and GV-APV cumulative amounts observed constitute regenerated 
APV. These results clearly suggest that pro-pro-drug (PPD) approach can result in enhanced 
oral and brain absorption provided with lowered affinity for efflux transporters, good affinity 
for influx transporters and good enzymatic stability.  
Conclusions 
 From the in vitro permeability evaluation it is clear that V-APV, VV-APV, 
and GV-APV exhibited better permeability compared to APV. However V-APV exhibited 
better permeability than di-peptide prodrugs. Observed enhancement in permeability of VV-
APV and GV-APV could be due to reduced affinity for efflux protein P-gp. V-APV 
exhibited better flux which is attributed to evasion of efflux and active transport. Transport of 
valine was characterized and found to be translocated via system L-amino acid transporter 
LAT1 with comparable affinity with tyrosine and phenylalanine. Considering in vitro 
stability, bioreversion and oral absorption results, GV-APV was evaluated from brain 
absorption along with V-APV. In vivo brain absorption studies clearly indicate the 
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concentration of regenerated APV from prodrugs is 1.5 to 2 times higher than APV. 
Moreover bidirectional functionality of LAT1 is well studied. Hence V-APV needs to be 
converted to APV in brain tissue. Our tissue homogenate stability study clearly demonstrated 
regeneration of APV from prodrugs. This couls be the reason for high concentrations of APV 
in brain parenchyma. All these results clearly prove that PPD approach is a viable strategy to 
improve brain absorption of antiviral agents resulting in better therapeutic efficacy.  
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CHAPTER 7 
SUMMARY AND RECOMMENDATIONS 
Summary 
Presence of efflux proteins on epithelial and endothelial membranes plays a major 
role in pharmacokinetic and pharmacodynamic properties of drugs. In the recent years 
importance of efflux proteins in drug therapeutic efficacy and drug-drug interactions is 
gaining importance. Hence the USFDA guidelines suggest that every new and existing drug 
should be studied for their affinity for efflux proteins such as P-glycoprotein (P-gp) and CYP 
metabolizing enzymes. Considerable amount of research has been performed to circumvent 
these efflux proteins by various approaches.  In this dissertation project nutrient transporter 
targeted prodrug approach has been employed to circumvent P-gp mediated cellular efflux. 
Besides efflux transporters, such as P-gp being expressed in the inner leaflet of the apical 
membrane, a number of nutrient transporters are also expressed on the outer leaflet of 
cellular membranes. These nutrient transporters are responsible for the influx of various 
nutrients and drugs into various epithelial cells (enterocytes) and endothelial cells (e.g. blood 
brain barrier). In the transporter targeted prodrug approach chemical modifications to drug 
molecule were made such that evasion of efflux and recognition by influx transporters occur 
simultaneously. 
In this dissertation project, Amprenavir (APV) was selected as model compound to 
test our hypothesis.  We attempted to improve both oral and brain absorption of APV 
simultaneously by prodrug derivatization.  Di-peptide and amino acid prodrugs (Val-APV, 
Val-Val-APV, and Gly-Val-APV) were synthesized and evaluated for interaction with P-gp. 
These prodrugs exhibited less affinity for P-gp mediated efflux and are good substrates of 
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peptide transporter expressed on intestinal epithelium. Moreover these prodrugs exhibited 
low protein binding and better metabolic stability compared to parent drug.  These prodrugs 
are readily converted to parent drug by enzymatic hydrolysis. These prodrugs underwent 
sequential hydrolysis, peptide hydrolysis followed by slow ester hydrolysis. Oral absorption 
studies demonstrated that prodrugs have very good oral absorption compared to APV.  VV-
APV and GV-APV exhibited significant increase in AUC values relative to APV. One 
important observation in oral absorption studies was, longer mean residence times of V-APV 
than other breakdown moieties of di-peptide prodrugs. High concentrations of amino acid 
prodrug in systemic circulation were observed. Permeability characteristics of prodrugs were 
studied using in vitro BBB model. All the prodrugs exhibited 2-3 fold better permeability 
than APV. Since V-APV is observed in systemic circulation in high amounts, we 
characterized transport of valine across BBB to investigate interaction of valine prodrug with 
system L amino acid transport system.  Finally brain absorption of APV and prodrugs was 
studied following intravenous administration in Sprague-Dawley rats. Only amino acid and 
parent drug were in brain following GV-APV administration. The AUC of regenerated APV 
from prodrug is at least twice higher than that of APV. From all the observations in this 
dissertation project, we can clearly conclude that this pro-drug/pro-pro-drug approach can be 
successfully employed to deliver PIs and other substrates of efflux proteins effectively. 
Recommendations 
Transporter targeted pro-pro-drug strategy evaluated in this project, is a viable 
strategy to circumvent efflux pumps expressed on both epithelial (intestinal) and endothelial 
(BBB) membranes. Utilization of nutrient transporters to translocate drugs can enhance oral 
and brain absorption of poorly permeable compounds. However knowledge about various 
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tissue specific transporters may aide in better tissue targeted delivery. Novel transporters 
such as histidine peptide transporter (PHT1) can be explored and utilized for drug delivery. 
Since ester hydrolysis of pro-drug to drug is rate limiting step in the current approach, 
various amino acid promoieties can be studied in terms of hydrolytic and metabolic stability. 
Better understanding of transporters expressed on both absorptive and secretory membranes, 
their functionality and directionality can result in various promoities which can be conjugated 
to drugs. This knowledge may help designing better prodrugs with improved apical influx 
and basolateral secretion at epithelial and endothelial barrier mebranes. 
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